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General aim and structure 
GENERAL AIM OF THIS THESIS 
 
Currently there is a growing interest in pulsed drug delivery systems, which release 
their drugs at programmed times. The general aim of this study is to evaluate a concept for 
pulsed drug delivery based on hydrogel microspheres (microgels) surrounded by a rigid 
semi-permeable membrane. Inside the microsphere a controlled degradation of the 
hydrogel polymer has to be found that results in an internal pressure build-up leading to a 
final pressure, which is sufficient to overcome the tensile strength of the surrounding 
membrane. When the membrane ruptures, all the drugs inside the microspheres must be 
liberated rapidly to create a pulse. This thesis is a first contribution to the search for a 
multiple pulsed drug delivery system schematically represented in Figure 1. A mixture of 
different types of self-exploding microparticles (e.g.: coated microgels bursting after one 
week,  two weeks and three weeks, respectively) could be injected subcutaneous by a 
‘single shot’. As most vaccination schemes demand a repetitive contact with the antigen 
for complete vaccination, our concept is potentially interesting to obtain ‘single shot 
vaccination’. 
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Figure 1. Drug delivery from coated biodegradable microgels which explode after 
different times resulting in multiple pulsed drug delivery after a single injection.  
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A real challenge is the exact timing of the rupture of the membrane creating the 
pulsed delivery of the drug. The strategy will be to determine what pressures are needed to 
rupture the membrane (depending on the size and composition of the microspheres, the 
thickness and strength of the membrane). 
 
The first key aspect of this thesis includes the search for a degrading (non-coated) 
hydrogel with a predictable pressure profile as a function of time. The focus in this thesis 
is on dextran based gels. It will be necessary to understand the mechanism of pressure 
increase and swelling. Indeed, before surrounding a microgel with a membrane we must 
understand how the hydrogel degrades and what mechanism leads to the increase of 
internal pressure – taking into account that no or only partial swelling will occur when the 
hydrogel is surrounded by the membrane. Both thermodynamics and reaction kinetics 
determine this phenomenon. The thermodynamic properties include the swelling pressure 
(Πsw) of the hydrogel which is described as the sum of two terms: an osmotic pressure 
(Πosm) that expands the network and an elastic pressure (Πel) that acts against expansion. 
The reaction kinetics of the hydrogels can be altered by changing the hydrogel 
compositions. 
 
The second key aspect of this thesis includes the evaluation of the mechanical 
properties of the membrane (surrounding the hydrogel core). As membrane material we 
preferred lipids. We wonder which membrane should be used to obtain a unique 
membrane surrounded microgel system which is able to release the entrapped drugs by 
osmotic bursting of the membrane due to hydrogel degradation.  
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STRUCTURE OF THIS THESIS 
 
Chapter 1 represents a literature overview on “programmed polymeric devices for 
pulsed delivery”. The last part of Chapter 1 introduces the concept of ‘self-exploding 
microparticles’ consisting of a hydrogel core and a semi-permeable membrane. To make 
exploding microcapsules is the final goal of this work. As core material dextran based 
hydrogels are used. As membrane we especially focus on lipids.  
Chapters 2-5 deal with the swelling pressure of dextran based hydrogels. As only a 
few references were found on swelling pressures of hydrogels, a method to measure the 
swelling pressure of degrading and non-degrading dextran hydroxyethyl methacrylate 
(dex-HEMA) hydrogels is proposed in Chapter 2. The results are further evaluated in 
terms of scaling concepts.  
In Chapter 3 we wonder whether we can describe the swelling pressure profiles of 
the degrading dex-HEMA gels by using non-degraded dex-HEMA gels containing 
different amounts of free dextran (i.e. degradation product). The dex-HEMA/dextran gels 
mimick partially degraded dex-HEMA hydrogels. Swelling pressure profiles of dex-
HEMA hydrogels with different compositions (degree of substitution and concentration at 
cross-linking) are also evaluated. 
Because the osmotic deswelling method developed in Chapter 2 is very time and 
material consuming, a hydrogel osmometer is developed for the characterisation of the 
thermodynamic properties of degrading hydrogels. (Chapter 4) After validation of the 
osmometer, both methods for swelling pressure measurement of degrading hydrogels are 
compared. 
Having established good methods for evaluation of the swelling pressure of 
degrading hydrogels (Chapter 2-4), the influence of the degradation mechanism on the 
swelling pressure is analysed in more detail. Chapter 5 describes how the swelling 
pressure of dextran gels changes as a function of time in case the gels are degraded at their 
cross-links or at their back-bone, respectively. Dex-HEMA, with a degradation 
mechanism different to that of the dex-MA/dextranase hydrogels are included in this 
study. Differences in elastic modulus, release of degradation products, swelling and 
swelling pressure curves are shown and explained. 
Chapter 6 deals with the mechanical properties of lipid membranes and is dealing 
with the final formulation: the ‘self-exploding microparticles’ (i.e. the lipo-beads). 
Membrane properties are evaluated by measuring the tensile strength of lipids with 
different compositions. Further a method for lipid coating of the dex-HEMA microgels is 
proposed. And, in the end, we show experimentally how degrading microgels can rupture 
their surrounding lipid membrane.  
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Abstract 
Pharmaceutical research strives to design drug delivery systems that 
respond to therapeutic needs. Considering the facts that physiological 
parameters (e.g. heart rate, blood pressure and plasma concentration of 
hormones, plasma proteins, enzymes) display constancy over time, drug 
delivery systems with a constant release profile have been designed. 
However, because of circadian rhythms in physiological parameters and 
pathological conditions (e.g. asthma, angina pectoris), the conventional 
paradigm concerning drug concentrations “the flatter the better” may not 
be what the organism may need. Instead, to correlate with our biological 
needs, 'precisely timed drug delivery', which could be accomplished with 
‘programmable dosage forms’, is required. Precisely timed drug delivery 
may maximize therapeutic efficacy, may minimize dose frequency and 
may reduce toxicity by avoiding side effects and drug tolerance. This 
paper outlines the concepts that have been proposed to release drugs in a 
pulsed manner from pharmaceutical devices.   
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CHAPTER 1 
 
INTRODUCTION 
 
A common feature of many current controlled release devices is that they provide a 
continuous release over a prolonged period of time. However, there are many applications 
in medicine where a non-uniform release profile would be more beneficial.1 For bioactive 
agents such as hormones, many have suggested that pulsed release may offer advantages 
over continuous release2-4 as hormones are generally secreted by the body in a pulsed 
manner. Also, a pulsatile drug release pattern could be advantageous for drugs with an 
extensive first pass metabolism, for drugs that develop biological tolerance when they are 
constantly present at their target site and for drugs that require dosing at night. Also, 
devices that could give pulses of drug release at well-defined times after injection could be 
used to provide ‘single-shot’ vaccines where the initial and booster doses are contained in 
one delivery system. Such devices could improve vaccination coverage by reducing the 
number of vaccination sessions required to generate immunity.  
 ‘Pulsed drug release’ is defined as the rapid and transient release of a drug after a 
predetermined off-release period. One way to classify 'pulsed drug delivery systems' is 
based on the physicochemical and biological principles that trigger the release. These 
devices are classified into ‘programmed’ and  ‘triggered’ drug delivery systems. In 
‘programmed’ delivery systems the release is completely governed by the inner 
mechanism of the device, i.e. the lag time prior to the drug release is controlled primarily 
by the delivery system. In ‘triggered’ delivery systems the release is governed by changes 
in the physiological environment of the device (biologically triggered systems) or by 
external stimuli (externally triggered systems).  
Some examples of biologically triggered pulsed delivery systems include the delivery 
of insulin in response to glucose levels5-7, the delivery of anti-inflammatory drugs in 
response to increased concentrations in hydroxyl radicals and hyaluronidase as may occur 
at inflammatory sites.8-10 
In externally triggered systems external stimuli such as magnetism11, ultrasound12, 13 , 
temperature changes14 , electrical effects and irradiation15-17 activate the drug release. 
Because Kost and Langer have recently reported on pulsed delivery by biological and 
external triggers18 , this manuscript aims to review pulsed drug delivery from programmed 
devices. We have focused especially on programmed drug delivery devices that are able to 
generate more than one pulse ('multiple pulse') and are of interest in treating diseases 
requiring repeated drug administration (see Sheme I).  
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Sheme I: Overview of the programmed polymeric devices for pulsed drug delivery. 
Figure 1 
 
 
 
 
 
 
Bulk eroding systems (19-35)
Surface eroding systems (36-42)
pulsed delivery by spontaneous hydrolysis of polymer device
pulsed delivery by enzymatic degradation of the device (43-46)
Pulsed delivery by degradation of  the device
Pulsed delivery by osmotic pumping (47-51)
Pulsed delivery by osmotic bursting (52-56)
Pulsed delivery by osmotic pressure of the device
Pulsed delivery by degradation and osmotic bursting of the device (57-59)
Programmed polymeric devices for pulsed drug delivery
 
Pulsed delivery by degradation of the device  
 
This section outlines the delivery systems designed for pulsed release based upon 
the spontaneous hydrolysis or enzymatic degradation of the polymer comprising the 
device. The major idea to obtain pulsed release from such degradable polymer devices is 
that drugs (especially those with a higher molecular weight) can be physically entrapped 
in the non-degraded polymer matrix, and upon polymer degradation the matrix releases 
the drug. A combination of polymer matrices, one degrading faster than the others, in a 
single device may create opportunities to design multiple pulsed drug release systems.  
Pulsed delivery by spontaneous hydrolysis of polymer devices  
 
Bulk-eroding systems 
D,L-polylactic acid (PLA) is the most established biocompatible polymer that 
undergoes bulk erosion in aqueous conditions by ester linkage hydrolysis. To alter the 
degradation rate of PLA, the polymer is co-polymerised with glycolic acid (GA). Cleland 
and co-workers19-22  prepared microspheres with different PLGA compositions to achieve a 
‘single-shot’ HIV-1 vaccine. In vitro release studies showed a substantial initial release of 
the antigen. After a lag of several weeks a continuous (not pulsed) release over a period of 
4 weeks occurred.19 PLGA microspheres were also investigated to achieve pulsed release 
of tetanus toxoid (Mw of 150 000 g/mol) and malaria antigens (Mw of 16 000 g/mol). 23-27  
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Figure 1A. In vitro release rates (in mg antigen per day and per mg microspheres) of 
tetanus toxoid antigen from spray-dried PLGA (50:50; (■)) and co-acervated PLGA 
(75:25; (●)) microspheres. 26 B. In vitro release of tetanus toxoid antigens from ‘oil-filled 
PLGA microcapsules’. The lactic acid/glycolic acid ratio was 50:50 (■) and 75:25 (●), 
respectively. 31  
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Figure 1A shows the typical in vitro release profile of tetanus toxoid antigens from PLGA 
microspheres.27 It is characterized by an initial release, due to diffusion of the antigen near 
the surface of the microspheres, followed by a booster release after a certain lag phase that 
depends on the degradation rate of the matrix. Typically, the booster release occurs over a 
period of several weeks. Pulsed release is not obtained from PLGA microspheres. 
Moreover, PLGA shows some well-known disadvantages. Firstly, the exposure of the 
antigen to the acidic microenvironment inside the degrading PLGA-microspheres may 
degrade the antigen, (although basic additives like Mg(OH)2 and Ca(OH)2 may stabilize 
the antigens 28, 29). And secondly, the encapsulated drugs, especially proteins, may react 
with erosion products (like glycolic and lactic acid monomers and oligomers).30  
Sanchez et al. developed ‘oil-filled PLGA microcapsules’31 to overcome the PLGA 
limitations (as protein denaturation) described above. The microcapsules consist of an oil 
core, which contains the antigen, surrounded by an outer PLGA shell. As shown in Figure 
1B, the time of tetanus toxoid release from the oil-filled microcapsules could be 
engineered by selection of an appropriate PLGA composition. The initial tetanus toxoid 
release could be substantially decreased by lowering the amount of GA. Also, by lowering 
the amount of GA the booster release occurred after 7 weeks instead of after 3 weeks. 
However, the booster release was once again not pulsed but continuous over several 
weeks.  
 Khoo and Thiel proposed PLGA based implants to obtain pulsed release of 
antigens.32 The implant consists of a core of antigen in dibasic calcium phosphate coated 
with Eudragit S 100, which dissolves above a pH of 7.0. In turn, the Eudragit S 100 layer 
is coated with a blend of PLGA and ethyl cellulose. After hydratation of the outer layer, 
PLGA degrades and forms pores. Consequently, the Eudragit layer dissolves causing 
hydratation of the core and release of the antigen. The use of the Eudragit layer greatly 
delays the initial drug release. As an example, vitamin B12 was released after a lag time of 
75 days. Co-administration of an uncoated and a coated implant resulted in pulsed release 
of antigens after respectively 1 day and 75 days, and allowed complete vaccination of an 
animal in a single handling.32   
Pharmaceutical formulation of proteins under aqueous conditions is highly desirable to 
avoid protein degradation, which may occur when using organic solvents as in the 
preparation of PLGA devices. The group of Hennink introduced degradable dextran based 
microspheres, formed in aqueous environments, for pulsed delivery of proteins.33 The 
dextran-hydroxyethylmethacrylate (dex-HEMA) microspheres degrade under 
physiological conditions due to hydrolysis of carbonate esters in the cross-links of the 
microgels. To obtain degradation controlled release and to avoid having the entrapped 
proteins passively diffuse from the microspheres, the initial mesh size of the dextran 
network is kept smaller than the hydrodynamic diameter of the encapsulated proteins. 
Figure 2 shows the in vitro release of IgG from dex-HEMA microspheres, which differ in 
cross-link density. The initial release was lower than 10% of the load. Increasing the 
cross-link density of the microspheres delayed the onset of release from 5 to 15 days while 
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the booster release occurred over a week, which is considerably shorter than observed for 
PLGA microspheres. To further lower the initial release and to enhance the loading of 
lipophilic drugs into the aqueous microspheres, drug loaded liposomes were entrapped in 
the dex-HEMA microspheres. In this way, intact drug carrying liposomes were released in 
a pulsed manner over a period of months. 34  
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Figure 2. In vitro release of IgG from degrading dex-HEMA microspheres.33 The dex-
HEMA concentration of the microspheres was 50% (w/w), while the degree of substitution 
(i.e. the amount of HEMA groups per 100 glucopyranose units) equalled 3 (■), 6 (●), 8 
(▲) and 11 (▼), respectively. 
 
A possible disadvantage of the dextran-based microgels described above is the use of 
chemicals to cross-link the dex-HEMA. The group of Okano focused on calcium alginate 
beads that were prepared through physical cross-linking of an aqueous alginate solution35 
and which degrade (dissolve) due to exchange of chelated calcium ions with sodium ions 
from the medium. They showed that sterical entrapment in the gels, which is necessary to 
avoid initial release, could only be obtained for high molecular weight compounds 
(dextran ≥ 145 000 g/mol). Also, the lag time was short; it increased from 0.5 to 8 hours 
by increasing the alginate concentration and size of the beads. By combining calcium 
alginate beads of three different diameters, three pulses of dextran release could be 
established. However, the bead sizes were ≥ 1 millimetre. Much smaller sizes would be 
necessary, thus reducing the already short delay times.  
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Surface-eroding systems 
 
Polyanhydride36,37 and poly(ortho)ester38 based matrices degrade by surface 
erosion because the hydrolysis of the polymer occurs faster than the water penetration into 
the matrices. Consequently, mass is lost more rapidly from the surface than from the bulk. 
This property may be attractive for pulsed delivery systems employing multi-laminated 
devices that consist of drug containing layers altered with (drug free) isolating layers. The 
length of both the lag times and the active delivery phases can be tailored by changing the 
type and thickness of the isolating and drug containing layers. 
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Figure 3A. Release of brilliant blue (BB; ■) and carboxyfluoresceïne (CF; ●) from a 
cylindrical polyanhydride device, which is schematically represented in the insert.37 The 
core contains CF while the mantle is loaded with BB. B. Release of BB (■) and CF (●) 
from the implant as shown in the insert.37 The core contains CF while the mantle contains 
BB. C. In vitro release of pyranine from the device shown in the insert. The PLGA ((■), Mw 
of 10 500g/mol) and PLA ((●), Mw of 30 000 g/mol) matrices are tempered.37  
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Göpferich and co-workers investigated the use of polyanhydrides in surface 
erodable implants.37,39,40 The first reported implants consisted of a core and a mantle 
(Figure 3A), respectively 4 and 6 mm in diameter, both made of poly(1,3 bis[carboxy 
phenoxypropane]-co-sebacic acid) (p(CPP-SA)). As shown in Figure 3A, brilliant blue 
(BB), which was entrapped in the mantle, was released immediately while 
carboxyfluorescein (CF), present in the core, was released after two days, being too short 
for many applications. To overcome this, they suggested a combination of surface and 
bulk eroding polymer layers (Figure 3B); a drug-loaded p(CPP-SA) core, surrounded by a 
drug free mantle of p(CPP-SA) which was then coated with PLA to prevent early erosion 
and drug release from the core. Finally, a mantle of p(CPP-SA) was applied, containing 
the drug to be released initially. Two pulses occurred (Figure 3B). BB was released 
immediately while CF release, delayed by the erosion of the PLA-layer, started after two 
weeks. The rapid release of BB from the mantle was explained by its high water solubility. 
When the less water-soluble CF was in the outer layer, a pulse that lasted for about one 
week was observed. It indicates that the release from the outer layer strongly depends on 
the hydrophilicity and probably also on the molecular weight of the drug. The implants 
described above were intended to locally treat brain cancer. Again, a problem of these 
implants is their size, certainly when several implants need to be inserted. Moreover, the 
onset of drug release has to be adjusted from days to months. Therefore, the drug-loaded 
p(CPP-SA) core was directly coated with PL(G)A to trigger the onset of drug release.39 
Only ‘tempered’ PLGA and PLA matrices (i.e. matrices that were thermally treated in 
silicon oil to close pores and cracks) showed a pulsed release of pyranine in vitro with an 
onset time of release on day 4 and day 70, respectively (Figure 3C). Experiments on mice 
in which the matrices were subcutaneously implanted39 suggested that the in vivo release 
is in reasonable agreement with the release results observed in vitro.   
Jiang et al. have recently proposed another laminated device for pulsed protein 
delivery.41 As the insert in Figure 4 shows, the cylindrical device consists of protein-
loaded layers and isolating polyanhydride layers which govern the lag time between the 
pulses. The cylindrical device is surrounded by a polycarbonate coat and shows one open 
end. It was observed that the inner alternate layers gradually degrade from the open end. 
An interesting feature is that in the drug layer the protein is complexed to a polymer (i.e. 
poly(methacrylic acid)/polyethoxazoline). This complexation, which is pH-sensitive, 
promotes protein stability in the acidic microclimate created during polyanhydride 
degradation. As shown in Figure 4, at low pH the complexation retains the proteins in the 
drug layer until the upper drug free polyanhydride layer degrades totally. For myoglobine 
and FITC-BSA  (Figure 4) sharp release pulses were obtained. Both the lag times and the 
duration of the pulses could be tailored by varying thickness and composition of the 
polyanhydride layers. Since the device is only useful for drugs that can be complexed to 
the polymer, Qiu et al. suggested using pH-sensitive degradable layers consisting of 
polyphosphazene.42 The release profiles depend on the type of drug: the more hydrophilic 
the drug, the more easily it diffuses out, seriously influencing the intervals between the 
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pulses. Lag times could be tailored from 18 to 165 hours and the duration of the pulse 
varied between 19 and 40 hours. As a contrasting test, a device was examined that was 
composed of polyanhydride isolating layers and drug loaded PEG (not pH sensitive) 
layers. Similar to most other eroding devices mentioned above, an initial burst of the drug 
was followed by a sustained release phase instead of a second pulse. Therefore, the 
combination of polyanhydride layers with a pH-sensitive layer seems to be providing 
passively degrading devices for multiple pulsed drug release. The major disadvantage of 
these systems for single-shot vaccination is their large size (2-3 mm diameter and 11-14 
mm height) and their complexity to manufacture (multi-layered). 
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Figure 4. In vitro BSA release (■) from the laminated device (see insert) reported by Zhu 
et al.41 In the protein layer the proteins are complexed to PMAA/PEO. The pH of the 
dissolution medium is also shown (+). 
 
Pulsed delivery by enzymatic degradation of the device 
 
Pharmaceutical matrices can also be degraded by incorporation of enzymes in the 
matrix during manufacturing. Franssen et al. studied enzymatic degrading dextran 
hydrogels.43 The model protein IgG along with dextranase was incorporated during 
polymerisation of methacrylated dextran (dex-MA). The release of IgG was fully 
dependent on the degradation rate of the gel, which was strongly affected by both the 
concentration of dextranase and the cross-link density of the gel. At low dextranase 
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concentration a delay in the release was indeed observed, while at higher concentrations of 
dextranase, the release of IgG started immediately. To obtain multiple release pulses, the 
authors suggested simultaneously injecting micron sized dex-MA hydrogel particles with 
different amounts of dextranase and/or different compositions. However, miniaturisation 
of the gels seemed to be difficult since the release from dextranase containing 
microspheres followed zero-order kinetics without lag time.44  
Kibat et al. designed another enzymatic degrading device.45 Phospholipase A2-
coated liposomes were encapsulated in alginate microgels further coated with polylysine 
(see insert in Figure 5). Following hydratation, the phospholipase degraded the 
phospholipids, thus allowing release of entrapped drugs by diffusion through the 
microcapsule. As Figure 5 shows, a delay in the release of bovine serum albumin was 
observed and depended on the amount of phospholipase used. Pulsed release in vivo was 
demonstrated following subcutaneous implantation in mice45: the hydrogel matrix 
protected the liposomes from degradation and dispersion in the body, the liposomes acted 
as a drug depot, while the polylysine coat prevented dissolution of the alginate gel in the 
physiological environment. 
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Figure 5. In vitro release of FITC-BSA from alginate-poly(lysine) microgels loaded with 
liposomes without phospholipase A2 (■) and with phospholipase A2 ((●) 1 Unit, (▲) 10 
Units).45   
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Similar to the device shown in Figure 4 41, Moriyama et al. described a non-
degradable silicone tube containing alternating dextran layers and PEG grafted dextran 
layers loaded with insulin. 46 The PEG domains prevented diffusion of insulin into the 
dextran layers. In vitro pulsed insulin release occurred after respectively 10 and 50 hours 
due to surface degradation by the (non-physiological) dextranase that cleaves dextran from 
both open ends of the silicone tube. A similar device that could be degraded by 
hyaluronidase, which is present in higher concentrations at inflammatory sites, was also 
proposed.8  
 
 
Pulsed delivery based on the osmotic pressure  
of the device 
 
Establishing a pressure (osmotic and/or swelling pressure) in a pharmaceutical 
device requires a membrane surround the device that is permeable by water but 
impermeable by the drug and the pharmaceutical ingredients. Delivery from such devices 
is not only controlled by the osmotic or swelling agent, but also by the water permeability 
of the membrane, which in turn, is governed by the composition and thickness of the 
membrane.  
 
Pulsed delivery by osmotic pumping of the device 
 
Osmotic delivery systems have achieved wide acceptance as they can deliver 
drugs at a constant rate, and are largely independent from the environment.47 However, 
researchers from Alza Corporation modified the osmotic pump to achieve pulsed delivery 
for circadian therapeutic requirements. 
A veterinary pulsed delivery system (for implantation or oral intake) was derived 
from the Higuchi-Leeper pump.48 Water diffuses through the semi-permeable membrane 
into the chamber containing a solution with excess solid salt. Due to the dissolution of the 
salt the osmotic pressure rises, which stretches the elastic cap. Once a critical pressure is 
produced, the orifice opens, releasing the drug as a pulse. The pressure then falls, the 
orifice closes, and the cycle repeats.   
The elementary osmotic pump Volmax® is used to treat nocturnal asthma by 
delivering a pulse of salbutamol several hours after being swallowed.49 Volmax® contains 
sodium chloride as the osmotic agent in the core. Sodium chloride also lowers the 
solubility of salbutamol. When the sodium chloride is expulsed after swallowing, the 
salbutamol quickly dissolves, which results in an abrupt increase in the release rate of 
salbutamol. Only a single pulse of the drug can be delivered by Volmax®. Moreover, the 
concept is only useful for delivery of drugs with specific solubility properties.  
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Figure 6. Blood concentration of methylphenidate hydrochloride after oral administration 
of a Concerta® (18 mg) capsule from which pulsed delivery is obtained by osmotic 
pumping.51 
 
Concerta®, used to treat attention deficit hyperactivity disorder (ADHD) for 
school-aged children, is a modified push-pull osmotic pump which releases 
methylphenidate hydrochloride in a pulsed manner.50,51 As shown in the insert of Figure 6, 
the Concerta® capsule comprises a tri-layer core surrounded by an immediate-release drug 
coat. The tri-layer core is composed of two drug layers and a push layer containing 
osmotic active components. In the gastro-intestinal tract, the drug coat dissolves within 
one hour, providing an initial dose of methylphenidate. Water can cross the semi-
permeable membrane, hydrating the push layer and the interior drug layers. The push layer 
causes the release of methylphenidate through the precision laser-drilled orifice on the 
drug-layer end of the capsule. As Figure 6 shows, an initial plasma concentration is 
reached in 1-2 hours. Five to six hours after being swallowed methylphenidate 
hydrochloride is suddenly released.51 
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Pulsed delivery by osmotic bursting of the device 
 
As early as 1975 Baker described the delivery of drugs by osmotic bursting of the 
device.52  Figure 7A shows the device consisted of a water permeable membrane that 
enclosed the core containing the drug and an osmotic attractant, such as NaCl or other 
salts. In an aqueous environment water is osmotically drawn into the core, which swells 
until the membrane ruptures and releases the already dissolved drug in a ‘single’ pulse 
(Figure 7). This process, which is basically governed by the osmotic pressure of the core 
and the strength of the membrane, has been mathematically described by Kuethe et al.53 
The concept is comparable with the osmotic pump design; however, the device does not 
have an orifice in the outer membrane. This fact makes it less expensive because laser 
technology, which drills the orifice in the outer membrane, is not necessary. 
Ueda et al. presented the ‘time-controlled exploding system’ (TES).54 TES, which 
has a four-layer spherical structure (see insert in Figure 7B), consists of a polystyrene core 
(3.2 mm in diameter) on which the drug is loaded. The penetration of water through the 
water insoluble membrane (e.g. ethylcellulose) hydrates the swelling agent (e.g. 
hydroxypropylcellulose). The expansion of the swelling agent destroys the membrane and 
subsequent rapid drug release occurs. The authors showed that the lag time could be 
precisely programmed by the thickness of the outer membrane. Oral administration of 
TES particles with different lag times shows potential for short term (hours) multiple 
pulsed drug delivery (see Figure 7B).  Since the pressure of the swelling agent destroys 
the outer membrane, the lag time is independent of the physicochemical properties of the 
encapsulated drug.  
An osmotic bursting implant was reported by Thiel et al.55 An antigen was 
included in a compressed core of Explotab® (sodium starch glycolate). The core was 
coated with a pH sensitive Eudragit S 100 film, which was again coated with an insoluble 
Eudragit NE30D film containing hydroxypropylmethylcellulose (HPMC) as a pore 
former. In an aqueous environment the HPMC in the outer coat dissolved, creating pores 
that allowed water to access the Eudragit S 100 coating (which dissolves at tissue pH). 
Consequently, the water enters the core, thereby swelling and rupturing the outer 
membrane, which results in a pulsed release of the antigen. In vitro, the release of antigens 
could be delayed for 14 to 26 days. Also in vivo pulsed antigen delivery has been achieved 
by co-administering coated and uncoated implants.   
To achieve pulsed release of antigens Cardamone et al. packed alternate active 
and spacer tablets into a water impermeable tube (5 cm in length by 8 mm in outer 
diameter).56 One end of the tube was plugged while the other end contained a swellable 
agent (‘driver tablet’) surrounded by a porous polymer cap. Water entered through the 
porous cap to swell the driver tablet, pushing the plug out of the tube. Hence, the surface 
of the first tablet was exposed to the environment.  
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livery by degradation and osmotic bursting 
ice 
 devices described above the increase in osmotic pressure, which governs 
se, is mainly controlled by the rate at which water flows through the 
ther recently devices have been reported where the degradation of the 
nes the kinetics of osmotic pressure increase. 
roup of Okano investigated the release from millimetre sized calcium 
 coated with a polyacrylamide layer (see insert in Figure 8).57 Drug release 
ium ions diffusing from the medium into the gel and exchanging with 
Consequently, alginate gels turns into alginate solutions increasing the 
re. This cracks the polymer coating resulting in a pulsed release of the 
re 8). Only for high molecular weight dextran  ( ≥ 145 000 g/mol) could the 
be suppressed to levels below 10% of the load. Applying thicker coats on 
lted in lag times of up to 60 hours. A fast booster release was observed. 
15
‘Programmed polymeric devices’ for pulsed drug delivery. 
Multiple pulsed deliveries of macromolecular drugs may be realized by mixing alginate 
beads with various coat thicknesses. However, the design of injectable micron sized 
alginate beads of this type could be a problem. 
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Figure 8. In vitro dextran (MW of 145 000 g/mol) release from calcium alginate beads 
respectively without coating (■) and with a polyacrylamide coating of 25 (●), 50 (▲), and 
75 (▼)µm thick.57 The insert shows the crack in a coat surrounding the alginate bead 
(loaded with FITC-dextran) after 24 hours exposure to buffer. 
 
Our group recently proposed a “degradation controlled exploding microcapsule” 
for pulsed delivery.58,59 As in the concept of Okano, the capsule would consist of a water 
permeable membrane (allowing transport of water and preventing large molecular weight 
drugs from leaving the capsule) and an entrapped gel. However, the entrapped gel would 
be biodegradable. In contrast to the alginate beads, where the sodium ion flux determines 
the rate at which the alginate turns into a solution, the degradation rate of the gel (through 
spontaneous or enzymatic hydrolysis) would govern the osmotic pressure increase and 
thus the time of explosion of the microcapsules. While the onset of release is rather short 
for the polymer coated alginate beads, much longer lag times would be obtained in this 
way. The major challenge to realize this concept will be the coating of the degrading gel 
core.  The membrane surrounding the gel has to be (i) very homogeneous, (ii) permeable 
by water, (iii) impermeable by the entrapped drug and the degradation products of the gel 
and (iv) rupture at the time the polymer gel turns into a polymer solution.   
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CONCLUSIONS 
 
This review shows that, especially within the last decade, different concepts and 
devices have been proposed for precisely timed drug delivery. The list of potential uses of 
programmed devices for multiple pulsed drug delivery becomes longer as our knowledge 
of chronotherapy rapidly grows. Examples include the pulsatile administration of 
gonadotropin releasing hormone (for the induction of fertility), vaccines, corticosteroids 
(in the treatment of adrenal insufficiency) to name but a few. However, research on most 
of the programmed drug delivery devices is still in the ‘concept phase’. Most systems are 
only for academic use, their performance in vivo has often not been tested while clinical 
results are clearly lacking. Obviously, the concepts and devices will have to be closely 
examined before they may be rendered applicable for practical use. Critical considerations 
are the biocompatibility of the pharmaceutical ingredients used, shelf life, ease and cost of 
large scale manufacturing, which appears to be complicated, requiring special equipment 
and many manufacturing steps.   
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Abstract 
 The variation of the swelling pressure of dextran hydroxyethyl 
methacrylate (dex-HEMA) hydrogels is determined as a function of the 
degradation time.  In the first stage of the degradation process a moderate 
increase in the swelling pressure is observed due to the decrease of the 
elastic pressure.  In this period the cross-link density of the polymer 
network gradually decreases but only a small amount of free polymer 
(dextran) is released.  Towards the end of the degradation process, 
however, a sudden increase in the swelling pressure occurs which is 
accompanied by the release of a major amount of dextran chains. It is 
demonstrated that the chemical composition of the network (dex-HEMA 
content and the number of HEMA groups on the dextran chains) strongly 
affects the degradation rate of dex-HEMA hydrogels.  These observations 
are important to design degrading hydrogel systems with tailored swelling 
pressure profile for pulsed drug delivery.  
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INTRODUCTION 
 
Hydrogels are well suited for biomedical applications because of their tissue 
compatibility. Non-degradable hydrogels have been extensively studied as diffusion 
controlled and swelling controlled drug delivery devices1,2.  Recently, there is a growing 
interest to evaluate biodegradable hydrogels for drug delivery applications3-6.  Sustained 
drug release from a degrading hydrogel is obtained when the initial mesh size of the 
network is smaller than the size of the drug molecules, since the latter cannot leave the gel 
before the network has been degraded1.  
Currently, there is a major interest in pulsed drug delivery in which the 
pharmaceutical device releases the drug at a pre-programmed time7-9.  Pulsed drug release 
can be achieved by creating a rigid, semi-permeable membrane around the degradable gel 
particle.  The role of the membrane is twofold: (i) allows the transport of small molecules 
(e.g. water molecules, ions) between the gel and the surrounding solution, (ii) prevents 
large molecules (e.g., proteins, polymeric degradation products) from leaving the gel.  
During degradation the gel gradually liquefies and the swelling pressure Πsw increases.  
When Πsw exceeds the tensile strength of the membrane it ruptures10, followed by a 
sudden release of the drug. The combination of different types of degradable coated gel 
particles could be of practical use in e.g. ‘single shot vaccination’ in which the initial and 
subsequent booster release of antigens could be obtained in one single injection.  This 
avoids problems inherent with repeat immunizations and leads to an increased patient 
compliance. 
Development of drug delivery devices with predictable release profiles requires the 
understanding of the thermodynamic and kinetic properties of the degrading hydrogel 
matrix.  In an earlier paper we investigated the kinetics of degradation of dextran 
hydroxyethyl methacrylate (dex-HEMA) hydrogels11,12.  In this system degradation is 
caused by the hydrolysis of the carbonate ester link formed between the methacrylate 
group and the dextran molecule (Figure 1).                     
O
O
OH
O
OH
O
O
O
O
O
 
Figure 1. Chemical structure of the monomer in dex-HEMA, i.e. glucopyranose 
substituted with HEMA.  
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 The aim of the present study is to investigate the effect of degradation on the 
swelling pressure of dex-HEMA hydrogels. Although the swelling behavior of polymer 
networks has been the subject of numerous investigations13-19, according to our knowledge 
the variation of the swelling pressure in degrading gel systems has not been studied 
previously. Osmotic swelling pressure measurements are performed at different stages of 
degradation. The variation of the elastic modulus and the amount of free dextran produced 
in the degradation process are also measured.  The results of the osmotic measurements 
are analyzed in the framework of the scaling theory.    
 
EXPERIMENTAL SECTION 
 
Dex-HEMA preparation and characterization  
  
Dex-HEMA batches were prepared and characterized according to a method 
described elsewhere20.  Dextran (Fluka, from Leuconostoc ssp.) with a molecular weight 
Mn of 19 000 g/mol was used.  The degree of substitution (DS, the number of HEMA 
groups per 100 glucopyranose residues of dextran) was determined by proton nuclear 
magnetic resonance spectroscopy (H-NMR) in D2O with a Gemini 300 spectrometer 
(Varian).  The DS of the samples used in the present study were 2.9, 5.0 and 7.5, 
respectively.   
Preparation and degradation of dex-HEMA hydrogels  
 
Dex-HEMA gels were made by radical polymerization of aqueous dex-HEMA 
solutions.  The solutions were prepared by dissolving dex-HEMA in a phosphate buffer 
(PB: 10 mM Na2HPO4, 0.02% sodium-azide, adjusted with 1 N hydrochloric acid to pH of 
7.0). The polymerization reagents were N,N,N',N'-tetramethylene-ethylenediamine 
(TEMED; 20% v/v in deoxygenated PB, pH of 8.5) and potassium persulfate (KPS; 50 
mg/mL in deoxygenated PB).  50 µL TEMED solution was added to 1 g polymer solution.  
After homogenization, 90 µL KPS solution was subsequently added to the system to 
initiate gelation.  All containers were coated with poly(ethylene glycol) (PEG, 20 000 
g/mol; 10% in PB) to reduce adhesion.  Gelation required approximately 1 hour at room 
temperature. The hydrogel slabs used in the rheological measurements were made in 
cylindrical molds (diameter 23 mm, height 2 mm).  For the other experiments gels were 
prepared in 2.5 mL polypropylene syringes (diameter 8.5 mm) from which the heads were 
sawn.  After gelation the gel samples (~ 0.3 g gel) were removed from the syringe and cut 
with a thin wire.  Degradation was studied in phosphate buffer (pH of 7.0) at 37 °C.  
Throughout this work the dex-HEMA concentration (%w/w) refers to the concentration at 
which cross-links were introduced.   
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Osmotic deswelling 
 
In order to follow the swelling pressure generated by a confined hydrogel (i.e. 
when coated) as a function of degradation time, osmotic deswelling measurements were 
performed on dex-HEMA gels using a method described by Horkay and Zrinyi16.  Gel 
specimens were surrounded by a semi-permeable membrane (Medicell dialysis bags, Mw 
cut-off between 12 000 and 14 000 g/mol).  Similar dialysis bags were used in the 
purification step of the synthesis of dex-HEMA20.    
After different degradation times gel samples were equilibrated with PEG-
solutions at 4 °C.  PEG (Merck, Mw of 20 000 g/mol) was dissolved in citrate buffer (9.44 
g/L Na2HPO4; 10.3 g/L citric acid and 0.2 g/L NaN3, pH 4.4).  The PEG concentration was 
varied in the range 0 - 12.5 g/100 mL.  It was verified (from rheological measurements) 
that further degradation of the dex-HEMA gels did not occur during the osmotic 
deswelling measurements12.  Equilibrium swelling was attained within 7 days.  The 
reversibility of the swelling process was checked. 
At equilibrium the swelling pressure of the gel is equal to the osmotic pressure of 
the PEG-solution.  The osmotic pressure of the PEG-solution was calculated from the 
equation21 
 
Π PE G = 1Mn + A2 c + A3 c
2⎡ 
⎣ ⎢ 
⎤ 
⎦ ⎥ . c R T × 10         (1)   
 
where R is the gas constant, T is the absolute temperature, c is the PEG concentration (in 
g/100 mL), and A2 and A3 are the second and third virial coefficient, respectively.  
According to the data reported by Edmond and Ogston22 for PEG (Mn of 20 000 g/mol), 
A2=2.59 10-5 (mol.102 mL)/g2  and A3=1.35 10-6 (mol.104 mL2)/g3.  
The dex-HEMA concentration of the gels was calculated using the relationship  
       
c = w dex− HEMA
w dex − HEMA × v1( )+ w e − wdex − HEMAρ⎛ ⎝ ⎜ ⎞ ⎠ ⎟ ⎡ ⎣ ⎢ 
⎤ 
⎦ ⎥ 
× 100    (2) 
where we is the weight of the dex-HEMA gel, wdex-HEMA is the weight of dex-HEMA 
determined gravimetrically after drying the gel in a vacuum oven at 50 °C, ρ is the density 
of the buffer and v1 is the specific volume of the dex-HEMA (v1 =0.72 mL/g)23.  The 
polymer volume fraction (ϕ) of the gels was calculated from the concentration of dex-
HEMA and v1. 
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Figure 2. Schematic presentation of the osmotic deswelling measurements. A. After 
cross-linking, the gels are surrounded by a semi-permeable membrane. Dex-HEMA 
hydrogel degradation occurred at 37°C in PB and PH of 7.0. B. After well defined 
degradation times, the bags were immersed in PEG-solutions of known concentration. 
Degradation was inhibited (4°C and pH of 4.4). C. After 7 days equilibrium swelling was 
attained and the polymer volume fraction (ϕ) was determined gravimetrically. The 
swelling pressure profiles are obtained by plotting the osmotic pressure of the PEG-
solutions versus the polymer volume fraction  of the (partially degraded) gels. The vertical 
line represents the pressure generated by a confined hydrogel (i.e. having ϕ= constant) 
during degradation. 
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Mechanical characterization of degrading hydrogels  
 
Rheological measurements were performed using an AR1000-N controlled stress 
rheometer from TA-Instruments.  To avoid slippage the acrylic top plate was covered by 
sandpaper (diameter 2 cm).  The bottom plate was replaced with a Plexiglas® plate with a 
roughened surface.  Measurements were done in oscillation mode at 1 Hz in the linear 
viscoelastic region of these gels by applying a constant strain of 0.5%.  After the 
measurements the hydrogel slabs were transferred into PB and stored at 37 °C.  Further 
details of this method were reported by Meyvis et al24.   
Determination of free dextran chains in dex-HEMA gels  
 
 The concentration of the free dextran in the dex-HEMA hydrogels was determined 
from a release experiment performed in phosphate buffer at 37 °C.  The amount of dextran 
chains in the solution was measured by gel permeation chromatography (GPC).  The 
system consisted of a high pressure pump (Waters M510), an injector (Waters U6K) and a 
differential refractometer (Waters 410).  250 µL sample was injected and a flow rate of 0.5 
mL/min was applied.  The dex-HEMA concentration was calculated from the height of the 
peak using a calibration curve (concentration between 0 and 2.5 mg/mL) obtained for the 
corresponding dex-HEMA (DS2.9, DS5.0 and DS7.5).  In the concentration range 
explored here the reproducibility of the GPC measurements is excellent (the correlation 
coefficient for linear regression exceeds 0.996 for each standard line).  
 
 
RESULTS & DISCUSSION 
 
Figure 2 shows the variation of the concentration of free dextran in different dex-
HEMA hydrogels as a function of the degradation time, t.  The dextran concentration, 
calculated from the amount of dextran released from dex-HEMA gels, refers to the initial 
volume of the (undegraded) gel.  In principle, this concentration corresponds to the 
concentration of free dextran molecules in degrading gel particles surrounded by a rigid 
semi-permeable membrane.  It appears in Figure 2 that first the sol fraction (unreacted 
dex-HEMA chains) leaves the gel.  This feature is independent of the degradation process.  
In the second region (delay region) a relatively small amount of dextran is released. 
Finally, when the majority of the cross-links are cleaved the liberation of dextran chains is 
significantly enhanced. The delay in the release of dextran is expected since a chain can 
only become free when all cross-links connecting it to the network are cleaved.   
 28
CHAPTER 2 
 
0 10 20 30 40 50
0
5
10
15
20
25
 DS2.9; 25%
 DS2.9; 30%
 DS5.0; 20%
 DS7.5; 20%
g f
re
e 
de
xt
ra
n/1
00
m
L 
ge
l
degradation time (days)
 
Figure 3. Variation of the amount of free dextran as a function of time in degrading dex-
HEMA hydrogels.  The data are the average of three independent measurements.  The 
continuous lines were drawn arbitrarily through the data points. 
 
Figure 3 shows the elastic modulus G’ as a function of the degradation time for the 
dex-HEMA gels studied in Figure 2.  This quantity exhibits a continuous decrease during 
the degradation process.  The decrease of G’ is significantly slower in gels having higher 
dex-HEMA concentration or higher DS.  It was found previously that both the initial dex-
HEMA concentration and DS affect the cross-link density of these networks24.  An 
apparent rate constant can be determined from the decrease of G’ by using the following 
relationship 
 
G’(t)=G’(0)exp(-kappt)       (3) 
 
where G(0)’ is the modulus of the undegraded gel and kapp is a constant.  The values 
displayed in Table I indicate that the variation of the modulus in these highly swollen gels 
can be reasonably described by a pseudo-first order hydrolysis kinetics, and kapp decreases 
with increasing cross-link density.  The latter result implies that degradation is slower in 
densely cross-linked gels.  
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Figure 4. Variation of the elastic modulus as a function of time in degrading dex-HEMA 
hydrogels.  The data are the average of three independent measurements.  The dashed 
curves show the least squares fits to equation 3.  
 
Tabel I:  Fitting Parameters to Elastic Modulus (G’) data (equation 3) 
________________________________________________________________ 
Gel Sample        G’(0)/kPa        kapp/day-1
_________________________________________________________________ 
DS 2.9; 25%     17.5 +/- 0.7       0.079 +/- 0.003        
DS 2.9; 30%     32.2 +/- 1.0       0.071 +/- 0.002 
DS 5.0; 20%        32.3 +/- 2.0        0.056 +/- 0.002 
DS 7.5; 20%     42.4 +/- 3.4         0.046 +/- 0.002 
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In order to reveal the effect of degradation on the thermodynamic properties we 
measured the swelling pressure Πsw at different stages of degradation.  The swelling 
pressure Πsw of a non-ionic gel can be described as the sum of two terms15: an osmotic 
pressure Πosm that expands the network, and an elastic pressure Πel that acts against 
expansion 
 
  Πsw = Πosm - Πel       (4) 
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Figure 5. Plot of the swelling pressure vs polymer volume fraction for dex-HEMA gels 
before degradation.  The legend shows the DS and the dex-HEMA concentration of the 
gels. Each measuring point is the mean value of measurements on three hydrogels, 
which were independently prepared.  The dashed curves show the least-squares fits to 
equation 5.  The image at the top shows a dex-HEMA gel shrunken in a PEG-solution 
while the image on the bottom shows the corresponding fully swollen dex-HEMA gel.   
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  Figure 4 shows the variation of the swelling pressure as a function of the polymer 
volume fraction for different undegraded dex-HEMA hydrogels. The continuous curves in 
Figure 4 are the least squares fits of the swelling pressure data to the equation16: 
 
Πsw = A ϕn – A ϕen-1/3 ϕ1/3      (5) 
where A is a constant that depends on the particular polymer-solvent system, ϕe and ϕ are 
the volume fraction of the polymer in equilibrium with pure buffer and PEG solutions, 
respectively.  For the exponent n scaling theory25 predicts n=2.31 (good solvent condition) 
and n=3.0 (Θ-solvent condition).  The values of A and n obtained from the fits to equation 
5 are listed in Table II.  As expected A depends on the chemical composition of the 
network.  The value of n is close to that predicted for good solvent condition.    
 
Tabel II: Parameters from the fit of the swelling pressure data to equation 5. 
 
sample degradation time 
(days) 
Volume fractiona A 
(kPa) 
n Rb
DS 7.5; 20% 0 0.1150 4554 2.35 0.999 
DS 5.0; 20% 0 0.1391 5767 2.33 0.999 
DS 2.9; 20% 0 0.1547 3587 2.33 0.999 
DS 2.9; 30% 0 0.1688 3231 2.36 0.981 
DS 2.9; 25% 0 0.1128 5562 2.36 0.998 
DS 2.9; 25% 3 0.0919 5563 2.34 0.997 
DS 2.9; 25% 6 0.0745 5554 2.35 0.997 
DS 2.9; 25% 10 0.0598 5487 2.34 0.997 
DS 2.9; 25% 15 0.0493 5337 2.30 0.997 
DS 2.9; 25% 27 <0.01 7920 2.33 0.993 
a volume fraction at equilibrium swelling 
b correlation coefficient 
 
 
The effect of degradation on the swelling pressure was studied on the sample 
having the shortest degradation time (Dex-HEMA DS2.9; 25%).  In Figure 5 is plotted the 
swelling pressure as a function of the polymer volume fraction measured at different 
stages of degradation (after 3, 6, 10, 15 and 27 days).  The Πsw vs ϕ curves are gradually 
shifted to the left as the gel degrades.  
 
 
 
 
 32
CHAPTER 2 
 
 
Figure 6.  Swelling pressure of DS 2.9 dex-HEMA hydrogels deswollen in PEG-
solutions. The dex-HEMA concentration at cross-linking was 25% (w/w). Before 
deswelling the hydrogels were degraded during 0, 3, 6, 10, 15 and 27 days, respectively. 
Each data point is the mean value of measurements on three hydrogels.  The dashed 
curves through the data points are the least-squares fits to equation 5.  The vertical line 
shows the increase in Πsw at ϕ=0.112.  
 
The parameters obtained from the fits of the swelling pressure curves of the dex-
HEMA gels to equation 4 at different degradation times (Table II, Figure 6) indicate that 
neither A nor n varies notably in the first 15 days of degradation.  It can also be seen that 
after 27 days (i.e., when the network is completely liquified) the value of A significantly 
increases.   
We note that similar deviation between the values of A obtained for cross-linked 
and uncross-linked polymers has been reported for other polymer/solvent systems26,27. The  
difference in the A values can be attributed to the decreased degrees of freedom of the 
chains once cross-linked. This can be examined in terms of the interaction parameter χ. 
According to equation 6 26:  
A =
kBT C 1− 2χ( )34( )
ks
3a3       (6) 
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wherein a is the length of a monomer, C is the polymer characteristic ratio, χ is the 
polymer-solvent interaction parameter, kB is the Boltzmann constant and ks is a constant of 
proportionality for a given polymer-solvent situation, the value of A decreases as χ 
increases. Indeed it has been established that χ for gels is greater than that for polymer 
solutions of equivalent polymer fraction.27,28 This increase in the interaction parameter 
may be  due to the reduction in configurational entropy imposed on the polymer-solvent 
interaction energies at the junctions and at the polymer chain interior28. However, a theory 
capable of describing these effects for prediction of A or χ has not yet been developed. 
The dashed line in Figure 5 shows the situation that occurs when the gel is 
surrounded by a rigid semi-permeable membrane. During degradation Πsw increases from 
0 kPa (swelling pressure of the fully swollen undegraded gel) to 49 kPa (swelling pressure 
of the totally degraded dex-HEMA gel).  The latter is the hydrostatic pressure required to 
maintain the initial concentration (ϕ=0.112) of the gel during the degradation process.  
We note that in general the entrapped drug is expected contribute to the osmotic 
response.  This effect depends on the drug load and the properties of the particular system 
(e.g., molecular weight of the drug and its interaction with the polymer matrix).     
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Figure 7.  Variation of A as a function of degradation time t.  Open symbols: partially 
degraded dex-HEMA gels; filled symbol: fully degraded dex-HEMA gel. 
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CONCLUSIONS 
 
Osmotic deswelling measurements were performed on degrading dex-HEMA 
hydrogels to estimate the swelling pressure developed during network degradation.  It is 
found that the degradation rate strongly depends on the initial dex-HEMA concentration 
and DS.  The variation of the swelling pressure at each stage of degradation is 
satisfactorily described by the equation Πsw = A(ϕn–ϕe,tn-1/3ϕ1/3), where ϕe,t is the 
concentration of the fully swollen gel at degradation time t, and A and n are constants.  In 
the earlier phase of the degradation process the swelling pressure gradually increases.  
This is caused by the decrease of the elastic pressure.  Towards the end of the degradation 
process a pronounced increase in the swelling pressure is observed.  This pressure change 
is accompanied by a sudden increase in the amount of dextran released from the gel.   
In drug delivery systems the osmotic pressure can cause the rupture of the coat 
surrounding the hydrogel particle.  Consequently, the knowledge of the variation of the 
swelling pressure during the degradation process is essential to design hydrogel systems 
that have a Πsw profile tailored for pulsed delivery of drugs.  
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Abstract 
   
 Swelling pressure measurements were performed on degrading 
dextran hydroxyethylmethacrylate (dex-HEMA) hydrogels.  In these 
networks the cross-links are hydrolysable carbonate ester bonds formed 
between methacrylate groups and dextran molecules.  It is demonstrated 
that dex-HEMA gels made in the presence of known amount of free 
dextran chains exhibit osmotic properties similar to those of partially 
degraded dex-HEMA gels.  The swelling pressure Πsw of degrading dex-
HEMA gels is controlled primarily by the cross-linked dex-HEMA 
polymer and the free dextran molecules, while the contribution of short 
poly-HEMA fragments (produced in the degradation process) is negligible.  
It is found that Πsw only slightly changes during the first 15 days of 
degradation.  Close to the end of the degradation process, however, a much 
faster increase in Πsw is observed.  The swelling pressure profile of these 
gels strongly depends on the concentration of the cross-linked dex-HEMA 
and its chemical composition (amount of HEMA groups per 100 glucose 
units).  
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INTRODUCTION 
 
In the field of drug delivery there is a growing interest in biodegradable 
hydrogels.1-5 To achieve pulsed drug delivery we propose a new concept based on the 
controlled variation of the swelling pressure of degrading hydrogels.  We envision a 
delivery device that consists of a micron sized degradable gel particle surrounded by a 
water permeable membrane (Figure 1).  As the gel gradually dissolves the swelling 
pressure (Πsw) increases.  When Πsw exceeds the tensile strength of the surrounding 
membrane, the membrane ruptures and the drug is promptly released.  In this ‘degradation 
controlled exploding system’ the release of the drug is governed by the degradation 
kinetics of the hydrogel particle. In this respect it is similar to the bursting capsules 
outlined in the patent of Baker,6 and modeled by Kuethe et al.7 The difference being that 
these devices rely on the degradation of a hydrogel whereas the system of Baker relies on 
small molecular weight compounds. 
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and the dextran molecules.  As the gel degrades free dextran chains as well as short poly-
HEMA fragments are produced.  We found that Πsw after a weak initial growth exhibited a 
steep increase close to the end of the degradation process.  
This knowledge of the variation of Πsw during gel degradation is important to 
design pulsed delivery systems with tailored swelling pressure profile.  Here we 
investigate the effect of different factors that influence the kinetics of degradation and 
Πsw. The degree of substitution (DS, which is the amount of HEMA groups per 100 
glucose units) and the initial concentration of dex-HEMA are varied.  Furthermore, a 
comparison is made between Πsw of degrading dex-HEMA gels and dex-HEMA/dextran 
gels. The latter system, containing controlled amounts of free (unattached) dextran chains, 
mimics partially degraded dex-HEMA gels since dextran is liberated as degradation 
proceeds.  These investigations are expected to provide insight into the swelling properties 
of degradable dex-HEMA gels that may help to design ‘membrane coated’ gel systems for 
drug delivery after a certain lag time.  
 
EXPERIMENTAL SECTION 
 
Dex-HEMA preparation and characterization  
  
The synthesis and characterization of hydroxyethylmethacrylated dextran was 
performed as described by Van Dijk-Wolthuis.13 The number average molecular weight 
(Mn) of dextran (from Leuconostoc mesenteroides, Merck) and poly-HEMA were 19 000 
g/mol and 1300 g/mol, respectively. (For the dextran Mw/Mn of 2.1 was found.)  The 
degree of substitution (DS), defined as the number of HEMA groups per 100 glucose 
units, was determined by proton nuclear magnetic resonance spectroscopy in D2O with a 
Gemini 300 spectrometer (Varian). Three batches of dex-HEMA with degree of 
substitution 2.9; 5.0 and 7.5, respectively, were prepared. 
 
Preparation of dex-HEMA hydrogels and dex-HEMA/dextran hydrogels  
 
Dex-HEMA hydrogels were prepared by radical polymerization of aqueous dex-
HEMA solutions. The solution was prepared by dissolving dex-HEMA in phosphate 
buffer (PB: 10 mM Na2HPO4 adjusted with 1 N HCl to pH of 7.0). The polymerization 
reagents were N,N,N',N'-tetramethylene-ethylenediamine (TEMED; 20% v/v in 
deoxygenated PB, pH adjusted to 8.5 with HCl) and potassium persulphate (KPS; 50 
mg/mL in deoxygenated PB).  The gelation process was initiated by 50 µL TEMED 
solution and 90 µL KPS solution (per gram hydrogel). Gelation required approximately 
1.5 hours. The extractable sol fraction of the dex-HEMA gels was less than 3%. 
Dex-HEMA/dextran hydrogels were made using the same procedure in the 
presence of known amount of dextran. The solutions were prepared by dissolving dex-
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HEMA and dextran in phosphate buffer. The dextran was the same as used in the dex-
HEMA synthesis.   
Hydrogel slabs used for the rheological measurements were made separately in 
cylindrical molds (diameter 2.3 cm, height 2 mm). 
 
Swelling pressure measurements 
 
Osmotic deswelling measurements were performed on degrading dex-HEMA 
gels using a method described by Horkay and Zrinyi.9  Deswelling was achieved by 
enclosing the gels in a semipermeble membrane (Medicell dialysis bags, Mw cut-off 
between 12 000 and 14 000 g/mol). surrounded by aqueous poly(ethylene)glycol (PEG) 
solutions of known osmotic pressure.  At equilibrium, the swelling pressure of the gel in 
the dialysis bag is equal to the osmotic pressure exerted by the PEG solution outside.  
After different degradation times dex-HEMA gel samples were equilibrated with PEG 
solutions at 4 °C.  PEG (Merck, Mn of 20 000 g/mol) was dissolved in citrate buffer (9.44 
g/L Na2HPO4; 10.3 g/L citric acid and 0.2 g/L NaN3, pH of 4.4).  It was verified that 
further degradation of the dex-HEMA gels did not occur during the measurements. 
Equilibrium swelling was attained within 7 days. The reversibility of the swelling process 
was checked.   
The swelling pressure of gels prepared in the presence of free dextran chains was 
determined by a home-built ‘swelling pressure osmometer’. This device consists of a 
callibrated transducer (Honeywell), a sample chamber (volume: 4.2 mL) and a buffer 
chamber (filled with 15 mL PB at pH of 7.0).  The chambers are separated by a semi-
permeable membrane (Medicell, Mw cut-off between 12 000 and 14 000 g/mol) supported 
by a porous Bekipor® frame which is further supported by a teflon perforated cylinder. 
The membrane is permeable to small molecules (water and ions) but impermeable to large 
dextran molecules. (The low molecular weight fraction of the dextran was removed by 
dialysis prior to the swelling pressure measurements.)  The apparatus measures Πsw  up to 
7 atmospheres.  Πsw measurements were performed on gels made in the sample chamber 
12 hours after the preparation (i.e., before substantial degradation occurred).  
Measurements were made at 4 °C preventing hydrolysis of the dex-HEMA/dextran 
hydrogels. The experimental error of the swelling pressure measurements was found to be 
less than 5 %.  
 
Rheological characterization of the hydrogels 
 
 Rheological measurements were performed by an AR1000-N controlled 
stress rheometer from TA-Instruments according to a method described in detail by 
Meyvis et al.15 The elastic moduli of the gels were obtained from measurements made in 
oscillation mode at 1 Hz in the linear viscoelastic region by applying a constant strain of 
0.5%.   
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RESULTS & DISCUSSION 
 
In Figure 2A, a part of the osmotic deswelling profiles is presented for dex-
HEMA hydrogels (DS2.9; 25%) degraded during 0, 3, 6, 10, 15 and 27 days, respectively. 
Considering the reversibility of the deswelling process, a dex-HEMA gel is able to 
develop a swelling pressure (y-axis in Figure 2A) equal to the osmotic pressure to which it 
was submitted. Prediction of the evolution of the swelling pressure of a coated degrading 
dex-HEMA hydrogel was obtained in two steps. First, dex-HEMA hydrogels were 
degraded, resulting in a swelling as a function of degradation time. This is reflected in the 
Πsw vs ϕ plots which gradually shift to the left as the gel degrades. After different 
degradation times, the degradation was inhibited and the hydrogels were deswollen with 
PEG-solutions to the initial polymer volume fraction of the non-degraded hydrogel. The 
values on the vertical line in Figure 2A, represent the pressure necessary to keep the 
polymer volume fraction of a coated dex-HEMA hydrogels constant during degradation. 
In order to compare the swelling pressures of the dex-HEMA/dextran gels (measured in 
the swelling pressure meter) with the swelling pressures of the dex-HEMA hydrogels 
(measured with osmotic deswelling), the initial polymer volume fraction is 0.151 instead 
of 0.113, representing the relaxed or non-swollen state in stead of the swollen state of the 
gels.  
In Figure 2B is presented the variation of Πsw of a dex-HEMA gel obtained from 
swelling pressure measurements as a function of the degradation time t.  The figure also 
shows the osmotic (Πosm, t) and elastic (Πel, t) components of the swelling pressure 
calculated by the following equation:9; 16; 17 
 
 
3
1
3
1
,,, ϕϕϕ −−=Π−Π=Π nenteltosmtsw AA     (1) 
 
 
where ϕ and ϕe is the polymer volume fraction of the cross-linked dex-HEMA in 
the non-degraded gel (with φ = 0.151 ± 0.006) and of the cross-linked dex-HEMA in the 
fully swollen gel after degradation time t, respectively, A is a constant and n is a scaling 
exponent that depends on the thermodynamic quality of the solvent. In the analysis of the 
swelling pressure data A and n were iteratively adjusted to minimize the variation of the 
Πsw for each set of data points.  The resulting values of A and n are displayed in Table II of 
chapter 2.  
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Figure 2A. A part of the swelling pressure curve fittings (see Figure 6 of Chapter 2) of 
the degrading dex-HEMA (DS of 2.9) hydrogels is represented. The dex-HEMA 
concentration at cross-linking was 25% (w/w). The vertical lines show the increase in 
swelling pressure at  ϕe = 0.113 and at  ϕ = 0.151, respectively. B. Osmotic pressure 
(open bars), elastic pressure (black bars) and swelling pressure (gray bars) of dex-HEMA 
hydrogels (DS2.9;25%) during degradation. The swelling pressure was obtained from 
osmotic deswelling measurements with a constant ϕ = 0.151 (see Figure 2A), while the 
elastic and osmotic pressures were calculated from the measured swelling pressure by 
equation 1. 
 43
Tailoring the swelling pressure on degrading dex-HEMA hydrogels 
 
Figure 2B shows that Πel decreases and Πsw increases as the gel degrades (i.e., 
the carbonate ester cross-links are hydrolyzed).  In the first 15 days of the degradation 
process no appreciable change in Πosm can be observed.  (After 15 days this dex-HEMA 
gel became too weak to manipulate and to make swelling pressure measurements.) At the 
end of the degradation, when the dex-HEMA gel turned into a polymer solution, osmotic 
pressure measurements were performed.  This ‘gel-sol’ transition is accompanied by a 
sudden increase in the osmotic pressure indicating significant differences between the 
osmotic properties of the cross-linked polymer and the corresponding polymer solution.   
Similar observations have been reported for other polymer/solvent systems.18; 19 
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Figure 3.  Osmotic pressure of totally degraded dex-HEMA gels (DS 2.9; ●) and dextran 
solutions (■) as a function of the concentration.  
 
In order to estimate the osmotic contribution of the degradation products (low 
molecular weight poly-HEMA fragments and free dextran chains) we compared the 
osmotic pressure of a totally degraded dex-HEMA gel and that of a dextran solution 
(Figure 3). The good agreement between the numerical values indicates that poly-HEMA 
fragments do not make a significant contribution to the swelling pressure of degrading 
dex-HEMA gels. This finding is consistent with the expectation that low molecular weight 
degradation products (from GPC measurements MW(poly-HEMA) < 1300 g/mol) diffuse 
through the semipermeable membrane and leave the gel matrix. 
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Figure 4.  Osmotic pressure (open bars), elastic pressure (black bars) and swelling 
pressure (gray bars) of dex-HEMA/dextran hydrogels containing increasing amounts of 
free dextran chains.  The DS of the dex-HEMA is 2.9.  The total polymer volume fraction 
(dex-HEMA + free dextran) is 0.151 (± 0.006) for all the gels.  The values on the x-axis 
indicate the volume fractions of free dextran in dex-HEMA/dextran gels. 
 
Figure 4 shows the dependence of Πsw, Πel and Πosm on the volume fraction of 
free dextran chains ϕdextran in dex-HEMA gels prepared in the presence of known amounts 
of dextran (dex-HEMA/dextran gel).  Πsw was measured by the swelling pressure 
osmometer, Πel was estimated from elastic modulus measurements using the relationship 
Πel = G’, where G’ is the shear modulus, 20; 21 and Πosm was calculated from Πsw and Πel 
by equation 1. The dextran concentration on the x-axis corresponds to ϕdextran in degrading 
dex-HEMA gels after degradation times 0, 3, 6, 10, 15 and 27 days, respectively. The 
amount of free dextran was calculated from dextran release data of dex-HEMA gels 
measured by GPC (see ref.12). Figure 4 shows that Πel decreases, Πsw increases, and Πosm 
only weakly varies as the volume fraction of free dextran increases. Upon approaching the 
gel-sol transition, however, Πosm rapidly increases.  Clearly, the behavior of these dex-
HEMA/dextran gels is similar to that of partially degraded dex-HEMA gels. 
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In Figure 5 the quantity Πsw + G’ is plotted as a function of ϕdextran for dex-
HEMA/dextran gels. These gels differ in the degree of substitution (2.9<DS<7.5) and the 
total polymer concentration (cross-linked dex-HEMA + uncross-linked dextran). In the 
Figure is also shown the concentration dependence of the osmotic pressure of the uncross-
linked dextran solution. At low dextran concentration (ϕdextran < 0.1) Πsw + G’ is primarily 
governed by the polymer concentration. As ϕdextran increases Πsw + G’ exhibits an increase 
and gradually approaches the osmotic pressure of the dextran solution.  
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Figure 5.  Πsw + G’ for dex-HEMA/dextran hydrogels containing increasing amounts of 
free dextran.  The DS and the total polymer concentration (dex-HEMA + dextran) of these 
gels are as follows: DS2.9; 25% (●);   DS2.9; 30% (▲) ; DS3.5 ;20% (♦);   DS5.0; 20% 
(▼);   DS7.5; 20% (■).  The values on the x-axis indicate the volume fractions of the free 
dextran in dex-HEMA/dextran gels.  The continuous line shows the osmotic pressure of 
the uncross-linked dextran solution (+).   
 
To develop a degradation controlled exploding system as a platform for pulsed 
drug delivery, it is desirable to design hydrogels that possess different degradation 
kinetics.22; 23 In Figure 6 are presented swelling pressure versus degradation time plots 
obtained from swelling pressure measurements of dex-HEMA/dextran gels in conjunction 
with dextran release data of degrading dex-HEMA gels (see Figure 2 Chapter 2). As 
swelling pressure measurements are performed on hydrogels in the non-swollen state 
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(relaxed state), the data of the release experiments were also recalculated towards gels in 
their relaxed state.  The composition of these systems corresponds to that of various dex-
HEMA hydrogels at different stages of degradation.  In Figures 6 A and B the influence of 
dex-HEMA concentration is depicted.  The initial value of the elastic modulus, the height 
of the ‘plateau’ region of the osmotic pressure plot, and the degradation time increase with 
increasing dex-HEMA concentration.  Figures 6 C and D illustrate the effect of DS. 
Increasing DS increases the amount of possible cross-links. Generally, increasing the 
cross-link density (due to increasing either DS or dex-HEMA concentration) lengthens the 
degradation time and, consequently, the time required to attain a certain swelling pressure. 
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Figure 6(A-D).  Variation of the elastic (●), osmotic (▲) and swelling pressure (■) of 
different dex-HEMA hydrogels as a function of the degradation time. Symbols: (A) DS2.9; 
25% (B) DS2.9; 30% (C) DS5.0; 20% (D) DS7.5; 20%. Note that at low dextran 
concentration the dex-HEMA/dextran gel (DS7.5; 20%) exhibits phase separation, 
therefore, in this concentration range osmotic measurements were not be made. 
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CONCLUSIONS 
 
A systematic study was performed to gain insight into the effect of different 
factors (concentration of free dextran chains, degree of substitution, total polymer 
concentration) on the swelling pressure of degrading dex-HEMA hydrogels. In these 
networks the cross-links are hydrolyzable carbonate ester bonds formed between 
methacrylate groups and dextran molecules. It is demonstrated that dex-HEMA/dextran 
gels made in the presence of known amount of free dextran chains exhibit swelling 
pressure similar to those of partially degraded dex-HEMA gels. It is found that Πsw only 
slightly increases during the first 15 days of the degradation process. We showed that in 
this period Πosm of the gels did not change significantly. Close to the gel-sol transition, 
however, Πsw rapidly increases. The swelling pressure profile of these gels, particularly 
the variation of the swelling pressure in the final phase of gel degradation, strongly 
depends on the concentration of the cross-linked dex-HEMA and the chemical 
composition of the network chains.    
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Abstract 
   
 A new type of device is proposed that uses the sensitivity and 
reliability of a pressure transducer to measure the swelling pressure of 
complex systems as biodegradable hydrogels. In the proposed device, 
degradation induced changes in the swelling pressure of pharmaceutical 
hydrogels are measured by confining the hydrogel in an enclosure between 
a rigid semi-permeable membrane and the diaphragm of a pressure 
transducer. The concept of the osmometer is designed to keep the volume 
of the sample chamber constant during the measurements and hence to 
avoid swelling of the hydrogel. The sensor response time of the osmometer 
is checked. Validation of this device is performed using dextran and 
poly(ethylene)glycol solutions of known osmotic pressure. Values of the 
swelling pressure measured in the osmometer agree with literature values 
of the same solutions. The  osmometer has the potential to detect the effect 
of degradation on the thermodynamic properties as swelling pressure of 
pharmaceutical hydrogels. Knowledge of the swelling pressure and 
especially its evolution during degradation is extremely important for the 
design of new pulsatile drug delivery systems combining degrading 
hydrogels and osmotic bursting of a water-permeable coat.  
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INTRODUCTION 
 
In this work, knowledge of the evolution of the constant changing osmotic 
properties of a degrading hydrogel is essential.1-3 Not only the maximal reachable pressure 
value but also the evolution of the pressure profile, governed by the degradation kinetics 
of the hydrogel, will determine the time of osmotic bursting of the proposed exploding 
membrane surrounded microgels. The concept of performing pressure measurements in 
order to obtain hydrogel osmotic properties goes back at least 30 years to van de Kraats.4 
In more recent literature hydrogel osmotic properties were measured either by mechanical 
compression or by osmotic deswelling.5-7 However, the use of these techniques for 
evaluation of biodegradable hydrogels with constant changing properties as a function of 
time is limited. In 2002, Han et al. reported on a constant-volume hydrogel osmometer as 
new device concept for miniature biosensors.8 The necessity to make the gels outside the 
device (M-Biotech) and especially the large mesh size of the rigid semi-permeable 
membrane makes the concept not useful for our application. 
Figure 1A shows a conventional approach for biodegradable hydrogels. A 
biodegradable hydrogel is a cross-linked network that gradually liquefies in response to 
degradation. Degradation causes network destruction resulting in the increase of the 
swelling ratio and the release of degradation products as a function of time. However, for 
the determination of the osmotic properties of these biodegradable hydrogels, changes in 
network structure as well as the presence of degradation products will play a major role 
and will contribute to the swelling pressure measured. In Figure 1B, the same hydrogel is 
confined to a volume that is essentially constant, between a rigid porous membrane and a 
high performance pressure transducer. The membrane is only permeable to water and not 
permeable for the degradation products of the hydrogel. In this way, degradation products 
are prevented to leave the confined hydrogel. When degradation occurs, hydrogel 
properties change, water will diffuse into the hydrogel until the favorable energy of 
mixing is balanced by the increase in mechanical pressure within the enclosure. So, when 
a gel is constrained and can not reach its equilibrium swelling, pressure Π is build-up in 
the gel phase to compensate for the ‘gab’ in the chemical potential. Based upon this 
concept, a device was designed that should allow constant monitoring of the osmotic 
properties of biodegradable hydrogels. With the constant volume concept, the pressure and 
thermodynamic behavior of the hydrogel is very similar to its behavior in a drug delivery 
device consisting of a hydrogel core surrounded by a rigid semi-permeable membrane.  
 In this chapter the ‘osmometer or swelling pressure device’ is presented. The 
sensor response time is evaluated. Validation is performed with PEG and dextran solutions 
with known osmotic pressure. The swelling pressure of a dex-MA (DS3.1 ; 25%) hydrogel 
obtained with the osmometer and with the osmotic deswelling method, respectively, are 
compared. The applicability of the device as constant monitor of changing osmotic 
properties of biodegradable hydrogels is illustrated for an enzymatically degrading dex-
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MA hydrogel. The influence of enzyme concentration on the pressure profile is also 
shown. 
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Figure 1A. Swelling and liberation of degradation products from the unconfined 
biodegradable hydrogel. B. Biodegradable hydrogel at fixed volume, confined between 
the semi-permeable membrane and the diaphragm of the pressure transducer. 
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DESIGN OF THE OSMOMETER 
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Figure 2A. Photograph of the osmometer or swelling pressure device. 
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B 
Figure 2B. Schematic representation of the home-made osmometer. The hydrogel is 
moulded in the sample chamber resulting in perfect contact between pressure transducer 
and hydrogel and hydrogel and the semi-permeable membrane, which is supported on a 
porous wire frame. The water channels of the device are connected to a warm water bath 
allowing thermostatisation. The stainless steel pressure transducer is calibrated up to 690 
kPa.  
 
The home-made osmometer (which has also been called the swelling pressure 
device throughout this work) is illustrated in Figure 2. It is essentially a membrane 
osmometer. Compared with commercial membrane osmometers which are able to 
withstand pressures up to 0.01 atmospheres, the proposed osmometer is able to withstand 
much higher pressures (i.e. up to 7 atmospheres). Except for the constant volume hydrogel 
osmometer which has been proposed recently8, the use of commercial membrane 
osmometers is restricted to the pressure measurement of solutions (e.g. protein solutions 
with a molecular weight higher than 10 000 g/mol). To our knowledge, pressure 
measurement of hydrogels and more specifically measurement of the pressure changes of 
degrading hydrogels has not been reported.   
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The osmometer or swelling pressure device is built in stainless steel (18/10) and 
consists of a calibrated transducer (Stainless Steel Pressure Transducer Model AB/HP, 
Honeywell, 0-7 atmospheres), a sample chamber (4.2 mL) and a buffer chamber (15 mL). 
Both chambers are separated by a semi-permeable membrane supported by a porous filter 
frame (48 mesh, Bekipor®ST, Bekaert Fibre Technology) which is further supported by a 
teflon perforated cylinder. 
Based upon the molecular weight of the degradation products (formed during 
hydrogel break-down) a certain molecular weight cut-off (MWCO) is chosen for the semi-
permeable membrane. The lower the MWCO the slower the diffusion and the larger the 
equilibrium time which results in a longer sensor response time. Membranes with MWCO 
ranging between 100-14 000 g/mol are used. In order to keep the hydrogel confined to a 
constant volume the sample chamber is sealed. Evaporation of the buffer solution is 
prevented by sealing the buffer chamber. As the pressure is highly temperature dependent, 
the device is provided with water channels which are connected to a warm water bath 
(Hetofrig) to allow thermostatisation. During pressure measurements data are logged on a 
voltmeter (Consort, 0-100 mV). Pressures are calculated based upon the linear 
relationship: (Π (kPa) = 6,4898 . U (mV)), which was provided with the calibrated sensor 
of Honneywell.  
 
 
EXPERIMENTAL SECTION 
 
Preparation of polymer solutions  
 
Poly(ethylene)glycol and dextran solutions were prepared by dissolving the 
corresponding polymers, into phosphate buffer (PB:10 mM, Na2HPO4, 0.02 % 
sodiumazide, adjusted with 1 M hydrochloric acid to pH of 7.0). Poly(ethylene)glycol 
(PEG, Merck)  with a molecular weight Mn of 20 000 g/mol was used. Dextran (Fluka, 
from Leuconostoc ssp.) with a molecular weight Mn of 19 000 g/mol was used. The 
concentration of the polymer solutions ranged between 0 to 30% (w/v). About 5 mL of 
each sample was immersed in the osmometer. The pressure was measured at 25°C.  
 
Preparation of dex-MA/dextranase hydrogels 
 
Dex-MA/dextranase gels were made by radical polymerization of aqueous dex-
MA/dextranase solutions9,10. The DS of Dex-MA used in this study was 3.1 or 4.0. The 
solutions were prepared by dissolving dex-MA in a phosphate buffer (10 mM, pH of 7.0). 
Dextranase, the enzyme (D-1508 Sigma; diluted to 10 U/mL in PB, one unit liberates 1 
µmol of isomaltose per minute  at pH of 6.0 and 37°C) was added to the dex-MA solution 
(cooled to 4°C) prior to the addition of the gelation reagents. The polymerization reagents 
were N,N,N’,N’-tetramethyleneethylenediamine (TEMED: 20% v/v in deoxygenated PB, 
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pH adjusted to pH of 7.0 with hydrohloric acid) and potassium persulphate (KPS: 50 
mg/mL in deoxygenated PB). 50 µL of TEMED solution was added to 1 g of polymer 
solution. After homogenization, 90 µL of KPS was subsequently added to the system to 
initiate gelation. The gelating mixture was immersed directly  in the osmometer (cooled to 
4°C). On average a complete gelation took 90 minutes at 4°C. Throughout this work the 
concentration of the hydrogel was always 20-25% (w/w) and  refers to the concentration at 
cross-linking. 
 
Swelling pressure measurement 
 
Osmometer 
 
Πsw of the dex-MA/dextranase hydrogels was measured in the ‘home-made 
osmometer’. A Spectra Por® cellulose ester membrane with molecular weight cut-off of 
100 g/mol was used. The membrane is permeable to water but impermeable to the low 
molecular weight degradation products of the dex-MA hydrogels used in this study. 
Hydrogel gelation occurred at 4°C. After 12 hours of equilibration with the buffer, 
hydrogel degradation is allowed at 37°C. The buffer chamber is filled with PB (10mM, pH 
of 7.0) containing equimolar concentrations of KPS, TEMED and dextranase as used in 
the hydrogels. This is necessary because they are to large to migrate through the 
membrane and would contribute to the measured swelling pressure. 
For measurement of the osmotic pressure of the dextran and PEG-solutions, an 
equilibration time of 4 hours was respected. As semi-permeable membrane a Medicell 
dialysis bag with MWCO of 12-14000 g/mol was used.  
 
Osmotic deswelling 
 
Osmotic deswelling measurements were performed on degrading dex-MA gels 
using a method described by Horkay and Zrinyi.7 (see also Figure 2 of Chapter 2) 
Deswelling was achieved by enclosing the gels in a semi-permeable membrane (Medicell 
dialysis bags, MWCO between 12 000 and 14 000 g/mol) surrounded by aqueous 
poly(ethylene)glycol (PEG) solutions of known osmotic pressure. Equilibrium swelling (at 
4°C) was attained within 7 days.    
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RESULTS & DISCUSSION 
 
Evaluation of the sensor response time 
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Figure 3. Evaluation of the sensor response time by pressure measurement of a dextran 
solution (20% (w/w)) and of a dex-MA hydrogel (DS3.1; 20%) as a function of  
equilibration time.  
 
An ideal pressure device should be able to measure the osmotic or swelling 
pressure of a sample immediately when the sample comes in contact with the buffer 
solution. Therefore the response time of the sensor of the osmometer is checked for a 
dextran (20% (w/w)) solution and for a dex-MA hydrogel (DS3.1; 20% (w/w)). In both 
cases, a semi-permeable membrane with MWCO of 12-14 000 g/mol is used. As shown in 
Figure 3,  a constant pressure value is reached after 3 hours and 6 hours equilibration for a 
dextran solution and a dex-MA hydrogel, respectively. Therefore, in this work, a sensor 
response time of 4 and 12 hours is used for polymer solutions and hydrogels, respectively. 
In this way equilibrium osmotic and swelling pressure is assured before any swelling 
pressure measurement is performed. Han et al. published recently a miniature biosensor 
which is basically a similar system.8 For 0.3 mm hydrogels a response time of 20 minutes 
was obtained. Consequently, the long sensor response time of our device can be reduced 
substantially by using a miniaturised sample chamber reducing the thickness of the 
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hydrogel. As a very small deviation in the sensor diaphragm is necessary before detection 
of a signal, reduction of the sensor response time can be explained by the reduction of the 
diffusion time of water in the sample chamber with reduced lenght. As the diffusion of 
water in a polymer solution is faster compared to the diffusion of water in a polymer 
network the longer response time of the dex-MA gel towards the dextran solution (see 
Figure 3) is also explained. 
 
Measurement of the osmotic pressure of polymer solutions 
 
In Figure 4, the osmotic pressure of dextran-solutions and PEG-solutions are 
plotted as a function of polymer concentration. The reproducibility of the Πsw-
measurements was found better than ± 2%. As also shown in Figure 4, for both polymer 
solutions, dextran and PEG, similar pressure values were obtained as reported by Edmond 
and Ogston in 1968.11 Despite the similarity in molecular weight of both polymers used, 
higher pressure versus concentration values are obtained for PEG compared to dextran. 
This is explained by differences in polymer-solvent and polymer-polymer interactions. 
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Figure 4. Pressure measurement of dextran (■) and poly(ethylene)glycol (▲) solutions 
in the home-made osmometer in comparison with literature data of similar solutions, 
dextran (●) and PEG (▼), respectively).11 Measurements were performed at 25°C, after 4 
hours of equilibration with the buffer solution. The data are an average of at least three 
repeats. 
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Measurement of the osmotic pressure of hydrogels 
 
In Figure 5, a comparison was made between the swelling pressure of a dex-MA 
hydrogel (DS3.1; 25%) obtained by osmotic deswelling and obtained by the osmometer, 
respectively.  It takes about 69 kPa of additional osmotic stress (exerted by the PEG-
solution) to keep the volume of the dex-MA hydrogel fixed. If the sensor is accurate, it 
should take about 69 kPa of additional mechanical pressure to keep the hydrogel volume 
fixed. From Figure 5, the value measured with the sensor of the osmometer is  64 ± 10  
kPa, including hydrogel batch-to-batch variations. We consider both methods for swelling 
pressure measurement of hydrogels to be in acceptable agreement.  
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Figure 5.  Swelling pressure of a dex-MA hydrogel (DS 3.1; 25%) as measured by 
osmotic deswelling (open symbols) and by the constant volume hydrogel osmometer 
(closed symbol), respectively. The data are an average of at least three repeats. 
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Measurement of the osmotic pressure of degrading hydrogels 
 
In order to evaluate the osmometer as possible tool for monitoring constant 
changes in osmotic properties, an enzymatic degradable hydrogel system is chosen. 
Degradation of Dex-MA by the entrapped endoenzym dextranase results in the formation 
of small molecular weight degradation products. Therefore, a semi-permeable membrane 
of low molecular weight (MWCO of 100 g/mol) is necessary preventing the 
oligosaccharide degradation products like glucose, isomaltose, … 13, to leave the sample 
chamber. In Figure 6, the evolution of the swelling pressure of a degrading dex-MA 
hydrogel (DS of 4.0; 20% (w/w)) is plotted as a function of degradation time. The 
dextranase concentration is 0.25 U/g gel  and 0.5 U/g gel, respectively. Over the whole 
degradation period no degradation products were analytically detected  (for more details 
see 12) in the sample chamber. This indicates that no leakage of the low molecular weight 
degradation products occurred. In Figure 6, all curves show a saturating non-linear 
exponential increase in swelling pressure as a function of degradation time. This is 
conform our expectations as during the hydrogel degradation the increase in number of 
reducing oligosaccharides shows an identical profile (data not shown). Increasing the 
dextranase concentration results in a faster (two times) and a higher swelling pressure 
profile.  
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Figure 6. Pressure measurement of enzymatic degrading dex-MA hydrogels (DS4.0; 
20%(w/w)) in the osmometer. Influence of enzyme concentration is represented ((■) 0.25 
U/g gel and  (●) 0.50 U/g gel). Measurements are performed at 37°C. The data are an 
average of at least two repeats. 
 61
Development of an osmometer for swelling pressure measurement of degrading hydrogels 
 
Besides the degradation of dex-MA/dextranase hydrogels also the degradation of 
the dex-HEMA hydrogels was evaluated inside the osmometer. Unfortunately, dex-
HEMA hydrogel degradation was inhibited and could not be followed inside the device. 
Compared with unconfined hydrogels, less water is present when the gel is confined inside 
the sample chamber. This might explain why the dex-HEMA hydrogel degradation did not 
occurred in the time followed (about 100 days). 
 
Comparison between the osmometer and osmotic deswelling 
 
In brief, the pro and contra’s of both methods (i.e. the swelling pressure device and 
the osmotic deswelling) are discussed. Osmotic deswelling is an ‘indirect’ method for 
measurement of the swelling pressure of hydrogels. The hydrogels are first allowed to 
swell during degradation and are only afterwards deswollen towards the initial 
concentration (volume) of the non-degraded gel. Hence, the osmotic deswelling method 
provides pressure versus concentration plots making prediction of the swelling pressure of 
the membrane surrounded hydrogels possible, even when stretching of the membrane 
occurs. However, the osmotic deswelling method is extremely time and product 
consuming. In addition, at the gel-sol transition no swelling pressure measurements can be 
performed resulting in a loss of information at the end of the hydrogel degradation. 
However, compared with the osmometer, no expensive equipment is necessary. In the 
osmometer, the swelling pressure of the hydrogel is measured in a ‘direct’ way. During 
the measurement the hydrogel is confined to a constant volume and mimics the coated 
hydrogels as we assumed no stretching of the membrane. This might be not the case. The 
moulding of the hydrogel in the device is critical, especially inclusion of bubbles should 
be prevented. Hydrogels which tend to shrink after moulding (e.g. dex-HEMA DS7.5; 
20% (see Chapter 3)) cannot be measured in the device.  
 
 
CONCLUSIONS 
 
A new type of device is proposed that uses the sensitivity and reliability of the 
pressure transducer to measure the swelling pressure of complex systems as biodegradable 
hydrogels. The dimensions and material characteristics of the osmometer were optimized 
for the measurement of degrading hydrogels. In the proposed device, degradation induced 
changes in the osmotic swelling pressure of pharmaceutical hydrogels are measured by 
confining the hydrogel in an enclosure between a rigid semi-permeable membrane and the 
diaphragm of a pressure transducer. Sensor response time ranges between 3 and 6 hours 
for polymer solutions and polymer hydrogels, respectively. The device is validated by 
measurement the pressure of dextran and PEG solutions with known osmotic pressure. 
The pressure values are in good agreement with literature data. In order to further validate 
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the device the swelling pressure of a dex-MA (DS3.1; 25%) hydrogels is measured and 
compared with osmotic deswelling data of the same gel. It takes about 64 ± 10 kPa of 
mechanical pressure and 69 kPa of osmotic stress to keep the hydrogel volume fixed. 
Therefore both methods are considered to be in acceptable agreement. The device is able 
to monitor constant changes in osmotic properties of the enzymatic degrading hydrogel, 
i.e. dex-MA/dextranase gel. However, degradation of the dex-HEMA gels was inhibited 
inside the device and changes in osmotic properties could not be followed. In conclusion, 
depending on the type of hydrogel system and depending on its degradation mechanism 
the osmometer is a suitable alternative for the osmotic deswelling technique.   
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Abstract 
This study compares the behavior of dextran-based hydrogels that 
degrade through different mechanisms. The major aim is to investigate the 
influence of the degradation mechanism on the swelling pressure of the 
degrading hydrogels. The release of degradation products, the mechanical 
and swelling properties and swelling pressure of the degrading gels are 
measured. Two types of dextran-based hydrogels are investigated. Dextran 
methacrylate (dex-MA) hydrogels that are degraded by entrapped 
dextranase serve as a model for hydrogels that degrade by hydrolysis of 
the polymer backbone. Dextran hydroxyethyl methacrylate (dex-HEMA) 
hydrogels are used as a model for hydrogels that degrade at their cross-
links. The release of degradation products but especially the swelling 
pressure profile seems to be strongly dependent on the mechanism 
underlying the degradation of the gels. In case the dextran gels are 
degraded at their backbone the swelling pressure increases rather 
continuously, in case they are degraded at the cross-links it increases more 
discontinuously as a sudden increase occurs when the gels are (nearly) 
completely degraded. This study reveals that the increase in swelling 
pressure in degrading dex-MA/dextranse gels is (nearly) completely 
attributed to an increase in osmotic pressure. However, in degrading dex-
HEMA gels the increasing swelling pressure seems to be attributed to the 
decrease in elastic pressure (i.e. elasticity) of the gels. Indeed, during a 
substantial period the osmotic pressure of degrading dex-HEMA gels does 
not change. At complete degradation the maximal swelling pressure is 
obtained and equals the osmotic pressure of the solution of degradation 
products. A much higher maximal swelling pressure is obtained when the 
gels are degraded at their backbone than when degraded at their cross-
links.      
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INTRODUCTION 
 
There is a general interest in biodegradable polymer networks for use in 
controlled drug delivery devices.1 In addition, there is also a major interest in pulsed drug 
delivery devices which release the drug at pre-programmed times. Several concepts show 
potential to release drugs in a pulsed way.2 However, many of the proposed systems have 
several draw-backs like initial drug release (the so called ‘burst release’), sustained like 
release instead of pulsed release, … Our research group aims to develop ‘exploding 
microcapsules’ for pulsed drug delivery.3;4 We envision a delivery device that consist of a 
micron sized degradable gel particle surrounded by a water permeable membrane. As the 
microgel degrades the internal pressure rises resulting in a burst of the membrane followed 
by a fast drug release. The microgels in our study are degradable dextran-based hydrogels. 
As membrane components we investigate lipids and polyelectrolytes. The exploding 
microcapsules which we try to design should show a behavior comparable with the 
osmotic bursting of red blood cells  when immersed in a hypotonic solution. The 
difference being that the bursting in the microcapsules relies on the increase in swelling 
pressure of the degrading hydrogel core which, on its turn, depends on the degradation 
kinetics of that microgel. 
With this purpose in mind it is extremely important to be able to evaluate the 
degradation of the (dextran) microgel core and, especially, to understand which 
parameters govern its swelling pressure increase. In literature, mechanical properties, 
degree of swelling and release of degradation products are typically reported in studies on 
degradable hydrogels.5-9 In a previous paper of our group we also measured the swelling 
pressure of degrading hydrogels. We developed therefore a swelling pressure meter 
similar to the device described by Han et al.10 Furthermore we modified the osmotic 
deswelling technique as reported by Horkay et al.11 to measure the swelling pressure of the 
dextran-based hydrogels during degradation.  
Degradation of polymer networks can occur by different mechanisms: (i) by 
hydrolysis of side chains or pendant groups (ii) by cleavage of the polymeric backbone 
and (iii) by cleavage of labile groups in the cross-links. As shown in Figure 1, two types of 
dextran-based hydrogels, which degrade by different mechanisms, are investigated in this 
study: dextran methacrylate (dex-MA) hydrogels that degrade by cleaving the dextran 
backbone by the endoenzyme dextranase (entrapped within the hydrogel during 
polymerisation) and dextran hydroxyethyl methacrylate (dex-HEMA) hydrogels that  
degrade by hydrolysis of the cross-links that contain hydrolysable carbonate esters 
(between the methacrylate group and the dextran).12;13  
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dex-MA/dex-HEMA solution        dex-MA/dex-HEMA hydrogel
degraded dex-MA  hydrogel     degraded dex-HEMA hydrogel
dextranase H+/OH-
 
Figure 1. Schematic representation of the polymer network in dex-MA and dex-HEMA 
hydrogels. (o) represents glucose units in the dextran chains, ( ) represent the reactive  
methacrylate or hydroxyethylmethacrylate groups in dex-MA and dex-HEMA, 
respectively. The enzymatic hydrolysis by dextranase of the dextran chains in dex-MA 
gels and the  hydrolysis of the cross-links in dex-HEMA gels is also illustrated. 
 
The aim of this study was threefold. First of all, we aimed to evaluate how the 
degradation mechanism of the hydrogels influence the release of the degradation products, 
the mechanical and swelling properties of the gels. Secondly, we aimed to reveal how the 
swelling pressure of the gels changes during degradation and how this depend on the 
mechanism behind the degradation. Thirdly, based upon the release of the degradation 
products and the elasticity of the degrading gels we aimed to calculate the swelling 
pressure of the degrading gels. The calculated swelling pressure values were then 
compared with the experimentally measured values.   
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EXPERIMENTAL SECTION 
 
Preparation of the hydrogels 
 
Dex-MA and dex-HEMA were synthesized and characterized as described in 
detail elsewhere.14-16  Dex-MA and dex-HEMA were synthesized from dextran (from 
Leuconostoc ssp, Merck) with an average molecular weight of 19 000 g/mol. The degree 
of substitution (DS) of the dex-MA and dex-HEMA, which is the number of (HE)MA 
groups per 100 glucose units, equalled 3.1 and 2.9 for dex-MA and dex-HEMA gels, 
respectively.  
Dex-MA and dex-HEMA hydrogels were prepared by radical polymerization of 
aqueous dex-MA and dex-HEMA solutions, respectively. The solutions were prepared by 
dissolving the polymer in phosphate buffer (PB: 10 mM Na2HPO4, 0.02% sodium-azide, 
adjusted with 1 N hydrochloric acid to pH of 7.0).  The polymerization reagents were 
N,N,N',N'-tetramethylene-ethylenediamine (TEMED; 20% v/v in deoxygenated PB, pH 
adjusted to 8.5 with HCl) and potassium persulphate (KPS; 50 mg/mL in deoxygenated 
PB).  The gelation of dex-MA and dex-HEMA solutions was initiated by adding 50 µL 
TEMED solution and 90 µL KPS solution (per gram hydrogel). Gelation occured at 4°C.  
When “dex-MA/dextranase” gels were prepared, prior to addition of the gelation 
reagents, a dextranase solution (D-1508 Sigma; diluted to 10 U/ml in 10 mM PB pH of 
7.0; one unit will delivers 1 µmol of isomaltose per min at pH of 6.0 at 37°C) was added 
to the dex-MA solution (cooled to 4°C). Throughout this work the dextranase 
concentration in the dex-MA gels was always 0.2 U/g  gel. 
“Dex-HEMA/dextran” hydrogels were made by radical polymerization (as 
described above) of solutions containing both dex-HEMA and dextran (19 000 g/mol, 
Merck).  
   
Rheological characterization of the hydrogels 
 
Rheological measurements on the hydrogels were performed by an AR1000-N 
controled stress rheometer from TA-Instruments according to a method described in detail 
by Meyvis et al.6  
 
Characterization of the degradation products of the hydrogels  
 
Individual hydrogel slabs were submerged in 10 mL phosphate buffer (pH of 7.2) 
and stored at 37°C.  Samples (2.5 ml) were taken at regular time intervals and replaced by 
fresh buffer. Twice a day the containers were slightly shaken. 
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The concentration of reducing oligosaccharides released from the degrading dex-
MA hydrogels was determined spectrophotometrically with Sumner reagent as described 
by Franssen et al.17 In brief, 1.5 mL of Sumner reagent (0.2 g/mL sodium potassium 
tartrate, 10 mg/mL dinitrosalicylic acid, 10 mg/mL sodium hydroxide and 2 mg/ml 
phenol) and 100 µL freshly prepared sodium sulfite solution (30 mg/mL) were added to 1 
mL sample. This mixture was incubated for 15 minutes at 95°C. After cooling to room 
temperature, the absorbance was measured at 620 nm (Biochrom 4060 
spectrophotometer). The concentration of reducing oligosaccharides was calculated from a 
calibration curve using glucose solutions as a reference. 
 The concentration of dextran chains released from the degrading dex-
HEMA gels was measured by differential refractive measurements as described by Stubbe 
et al.3 
 
Swelling experiments 
 
To characterize the swelling behaviour of the degrading dextran hydrogels, they 
were weighed immediately after preparation (w0) and at several time points during their 
degradation (wt). The swelling ratio (Q) was calculated as follows: 
 
( ) 100%
0
0 ×−=
w
ww
Q t        (1) 
Swelling pressure measurements 
 
The swelling pressure (Πsw) of the dex-MA/dextranase gels was determined by a 
home-built ‘swelling pressure meter’. This device consists of a callibrated transducer 
(Honeywell, allows to measures Πsw  up to 7 atmospheres), a sample chamber (which 
contains the gel, volume 4 mL) and a buffer chamber (volume 15 mL).  The chambers are 
separated by a semi-permeable membrane (Spectra Por®, Mw cut-off 100 g/mol) supported 
by a porous Bekipor® frame which is further supported by a teflon perforated cylinder. 
The membrane is permeable to water but impermeable to oligosaccharides being the 
degradation products of dex-MA/dextranase gels. To measure Πsw of degrading dex-
MA/dextranase gels the sample chamber (cooled at 4°C) was filled with the dex-
MA/dextranase solution during gelation. The buffer chamber (also cooled at 4°C) was 
filled with PB at pH of 7.0 containing equivalent concentration of KPS and TEMED as 
present in the dex-MA/dextranase gels.  After moulding, dex-MA/dextranase hydrogels 
were allowed to equilibrate at 4°C (no substantial degradation of the gels occured) during 
12 hours. To start degradation the temperature of the device was increased to 37°C and 
Πsw values were registered as a function of time.   
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The swelling pressure meter seemed to be less suited to measure Πsw of 
degrading dex-HEMA gels. We observed that a dex-HEMA gel in the swelling pressure 
meter degraded slower than the same gel submerged in buffer. The reason is still unclear. 
Therefore, to measure Πsw of the dex-HEMA gels as a function of degradation time we 
worked as follows. The dex-HEMA gels were allowed to degrade during different times in 
phosphate buffer (pH of 7.0). Then the swelling pressure of the (partially) degraded dex-
HEMA gels was measured by ‘osmotic deswelling’ as described in detail by Horkay and 
Zrinyi.18  Deswelling was achieved by enclosing the (partially) degraded dex-HEMA gels 
in dialysis bags (Medicell, Mw cut-off 12-14 000 g/mol)  and submerging them into 
poly(ethylene)glycol (PEG, Merck, Mn of 20 000 g/mol) solutions of known osmotic 
pressure. Equilibrium swelling was attained within 7 days. At equilibrium, the swelling 
pressure of the (partially) degraded dex-HEMA gel (in the dialysis bag) equaled the 
osmotic pressure exerted by the PEG solution outside. As the deswelling in the PEG-
solutions occurred at 4°C, the dex-HEMA gels did not further degrade during the osmotic 
deswelling step (7days).  
 
 
RESULTS & DISCUSSION 
 
Dex-MA/dextranase hydrogels degrade through hydrolysis of the polymer 
backbone. As shown in Figure 1, the endodextranase, entrapped within the dex-MA 
network during polymerization, hydrolyzes the dextran chains of the polymer network. 
After a first cleavage of a dextran chain, the remaining strands (dangling ends) can be 
further degraded if they are long enough to fit within the active site of the dextranase.19 
Franssen et al. identified (by electrospray mass spectroscopy) the products obtained by 
enzymatic degradation of the dex-MA gels. E.g. for a dex-MA/dextranase hydrogel of DS 
4.0, they showed a variety of degradation products which are mainly oligosaccharides like 
glucose, isomaltose, … and monomethacrylated iso-maltotriose.19 In opposite, degradation 
of dex-HEMA gels through hydrolysis of the cross-links results in more well defined 
degradation products. As shown in Figure 1, hydrolysis of the carbonate ester cross-links 
results in the release of dextran chains and low molecular weight 
oligohydroxyethylmethacrylate fragments (from the cross-links).  
Figure 2 compares the release of degradation products, the rheological properties 
and the swelling behavior of degrading dex-MA/dextranase and degrading dex-HEMA 
gels, respectively. The dex-MA concentration in the (non-swollen) dex-MA/dextranase 
hydrogel was 25% (w/w) while the DS of  dex-MA was 3.1. Similarly, the dex-HEMA 
concentration in the (non-swollen) dex-HEMA hydrogel was 25% (w/w) while the DS of 
the dex-HEMA was 2.9.  
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dex-MA/dextranase hydrogel          dex-HEMA hydrogel  
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e 2. Cumulative release of the degradation products (i.e. oligosaccharides) (A), the 
 modulus (G’) (B) and the swelling (Q) (C) of degrading dex-MA/dextranase 
gels. The dex-MA concentration was 25% (w/w), the DS was 3.1 and the 
nase concentration was 0.2U/g gel. Cumulative release of the degradation 
cts (i.e. dextran) (D), the elastic modulus (G’) (E) and the swelling (Q) (F) of 
ding dex-HEMA hydrogels. The dex-HEMA concentration was 25% (w/w) and  the 
s 2.9. All data are the average of three independent measurements. 
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Figure 2A shows the amount of reducing oligosaccharides released from the 
degrading dex-MA/dextranase gel. A gradual increase in the amount of degradation 
products is observed as degradation proceeds: initially large amounts are released per time 
unit while the release rate slows down as degradation proceeds. This can possibly be 
explained as follows: the longer the degradation, the more likely that dextranase was 
released from the (degrading) dex-MA gel either in free form or bound to degradation 
products. Figure 2B shows the elasticity of the degrading dex-MA/dextranase gel. A major 
exponential decrease in G’ occurs during the initial part of the degradation: already after 2 
days the hydrogel lost the majority of its elasticity while after 7 days the gel became a 
solution. G’ only decreases when the dextranase degrades elastic network chains in the 
dex-MA gels. In opposite, the release rate of reducing oligosaccharides, is influenced by 
the action of the dextranase on both elastic and non-elastic dextran chains present in the 
hydrogel. The swelling of the degrading dex-MA/dextranase hydrogel is shown in Figure 
2C. The first point (at t = 0) concerns the hydrogel just after cross-linking, before any 
degradation occured (swelling ratio equals zero). The high swelling ratio after 1 day is 
mainly due to the change of the gel from its relaxed state into its swollen state (upon 
submerging in phosphate buffer). It was striking to observe that during the first days of 
degradation, the swelling ratio of the dex-MA/dextranase hydrogels hardly changed while 
the G’ of the hydrogels decreased considerably. This is explained as follows and 
schematically represented in Figure 3A. When an elastic network chain of the dex-MA gel 
is degraded by dextranase, the concentration of elastic network chains decreases and 
thereby also G’. However, due to the high functionality of the cross-links, the 
concentration of elastic cross-links will remain the same during a substantial time of the 
degradation process. As a consequence, the average molecular weight between the 
remaining cross-links is also unaltered, which does not allow the network to expand. 7 
Figure 2D shows the release of degradation products (i.e. dextran chains) from 
the dex-HEMA gels. In stead of an immediate release as observed for dex-MA/dextranase 
gels (Figure 2A), a rather retarded release of degradation products was observed for the 
dex-HEMA gels (Figure 2D): after the release of the sol fraction (being dex-HEMA chains 
not attached to the network during cross-linking), a lag phase occurs while towards the 
end of the degradation the release clearly occurs faster. The lag phase is explained by the 
fact that all cross-links connecting a single dex-HEMA chain to the network have to be 
broken before the chain can be released. The amount of dextran released at the end of the 
degradation equaled the initial amount of dex-HEMA used at cross-linking. A similar 
release of degradation products was observed by Lee et al. in their study on poly(aldehyde 
guluronate) hydrogels which also degrade through degradation of the cross-links.20 
Compared with the dex-MA/dextranase gels, G’ decreases more continuously during 
degradation of dex-HEMA hydrogels (Figure 2E). As illustrated in Figure 3B, the 
hydrolysis of each cross-link in a dex-HEMA gel decreases both the elastic chain and 
cross-link concentration which is reflected in the G’. However, we should be careful when 
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comparing G’ of degrading dex-MA/dextranase and dex-HEMA gels, as the degradation 
rate of the dex-MA/dextranase gels is strongly dependent upon the enzyme concentration. 
In Figure 2F the swelling behavior of the degrading dex-HEMA gels was followed. After 
an initial swelling observed upon submerging the relaxed dex-HEMA gel in buffer, the 
dex-HEMA gels swelled continuously during degradation. Note that a lag time in swelling 
was observed for the dex-MA/dextranase gel (Figure 2C).  As illustrated in Figure 3B, the 
hydrolysis of each cross-link on a dex-HEMA chain results in a longer network chain 
between the remaining cross-links. Consequently, these longer chains can expand which 
explains the continuous swelling of the hydrogels and which also explains the higher 
swelling of the dex-HEMA gels compared to the dex-MA/dextranase gels (Figure 3B).7  
 
 
  A: 
dex-MA/dextranase 
 
B: 
  dex-HEMA 
 
 
 
 
φ = 4 
φ = 0 
 
 φ = 4  
 
 
 
 
 
 
 φ = 3  
 
 
 
 
Figure 3. Schematic representation of the degradation of respectively a dex-HEMA 
network by dextranase (A) and a dex-HEMA network which degrades through hydrolysis 
of the cross-links (B). (φ) refers to the functionality of the cross-links (•).  
 
Besides being interested in how the degradation mechanism influences the release 
of degradation products, the rheological properties and the swelling behavior of the gels, 
we were especially interested to know how the swelling pressure of the two types of 
degrading gels builds up during degradation. Figure 4 shows that the swelling pressure of 
dex-MA/dextranase gels increases gradually during degradation. Besides Πsw, Figure 4 
also shows the osmotic pressure (Πosm) and the elastic pressure (Πel = G’) of the degrading 
dex-MA/dextranase hydrogels. Πosm was calculated from the experimentally measured 
Πsw and Πel using the following equation: 
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     Πsw = Π osm - Π el    (1) 
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Figure 4. Osmotic pressure (open bars), elastic pressure (black bars) and swelling 
pressure (grey bars) of degrading dex-MA/dextranase hydrogels (DS3.1;25% and 0.2U/g 
gel dextranase).    
 
 
Clearly, the increase in Πsw mainly originates from the increase in osmotic 
pressure and only slightly from the decrease in elastic pressure: the contribution of the 
elastic pressure to the swelling pressure  of degrading dex-MA/dextranase gels seems to 
be neglectable. In other words, the change in osmotic pressure of the dex-MA/dextranase 
gel nearly equals the change in swelling pressure. One can wonder why the swelling 
profile in Figure 2C does not follow the swelling pressure profile of the dex-
MA/dextranase gels in Figure 4. Clearly, in the swelling measurements in Figure 2C the 
degradation products were allowed to diffuse out of the gels and, consequently, did not 
contribute to the swelling profile. However, in the swelling pressure measurements in 
Figure 4 the degradation products stayed in the gel (as they could not diffuse through the 
semi-permeable membrane in the swelling pressure device) and contributed to Πsw. 
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Figuur 5A. Swelling pressure (as measured by the swelling pressure device) of 
degrading  dex-MA/dextranase hydrogels (DS 3.1; 0.2U/g gel dextranase) with different 
dex-MA concentrations: 20% (■), 25% (●) and 30% (▲). B. Osmotic pressure of 
degrading dex-MA/dextranase  gels as calculated from the release of  oligosaccharides 
(see Figure 2A) using equation 2. The data are the average of three independent 
measurements.  
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We further focused on the swelling pressure of degrading dex-MA/dextranase 
gels by varying the dex-MA concentration of the gels. Figure 5A shows the experimental 
results obtained with the swelling pressure device. The maximal swelling pressure, which 
is obtained when the dex-MA/dextranase gels are totally degraded, was higher for more 
concentrated gels. This was expected as, the higher the initial dex-MA concentration at 
cross-linking the higher the concentration of degradation products which increases Πosm 
and thus Πsw. Figure 5B shows the osmotic pressure of the degrading dex-MA/dextranase 
hydrogels in Figure 5A as calculated using the Van ‘t Hoff law:  
 
Πosm = c.R.T       (2) 
 
where c is the concentration (in mol/L) of oligosaccharides in the dex-
MA/dextranase gels as calculated from the oligosaccharide release experiments in Figure 
2A. R is the gas constant and T is the absolute temperature. Comparing Figure 5A and 5B 
reveals that the Πosm-profile, as calculated with equation 2, fairly corresponds to the 
experimentally obtained Πsw-profile in Figure 5A. This confirms that the swelling pressure 
of degrading dex-MA/dextranase gels can be easily predicted from their osmotic pressure 
as calculated from the amount of oligosaccharides released during degradation. 
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Figure 6. Osmotic pressure (open bars), elastic pressure (black bars) and swelling 
pressure (grey bars) of degrading dex-HEMA hydrogels (DS2.9;25%). After 15 days the 
dex-HEMA gels became to weak to manipulate and to make swelling pressure 
measurements. After 27 days, when the gel turned into a complete polymer solution, a 
final measurement could be performed.  
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Figure 6 shows that the Πsw-profile of dex-HEMA gels totally differs from the 
one of dex-MA/dextranase gels. In the first 15 days of the degradation process a gradual 
increase in swelling pressure was observed. However, the increase in Πsw is completely 
attributed due to the decrease in elastic pressure as no significant change in Πosm can be 
observed. Hence, the elastic contribution to Πsw cannot be neglected as is the case for dex-
MA/dextranase gels. Secondly, to the end of the degradation (when the gel becomes a 
solution), the swelling pressure suddenly increases which seems to originate from a 
sudden increase in osmotic pressure at the ‘gel-sol’ transition. Similar observations have 
been reported for other polymer/solvent systems.21;22  
In order to explain the osmotic pressure properties of degrading dex-HEMA gels, 
dex-HEMA gels were made in the presence of free dextran chains. As during degradation 
of the dex-HEMA gels dextran is released, the dex-HEMA/dextran gels mimic ‘partially 
degraded dex-HEMA gels’.4 In Figure 7 the osmotic pressure of a non-degraded dex-
HEMA gel (25% dex-HEMA DS 2.9) and of a dex-HEMA gel containing free dextran 
chains (12.5% dex-HEMA DS 2.9 and 12.5% free dextran)  is shown. Despite the fact that 
a high amount of free dextran chains is present in the dex-HEMA/dextran gel, there is no 
significant difference in osmotic pressure of these gels. Hence, the dextran chains present 
in the dex-HEMA gel do not behave as free chains but as additional network chains. 
Based upon light scattering experiments, Kloster et al.23-25 reported that the presence of a 
gel matrix reduces the entropy and hence the osmotic pressure of the free chains present in 
that gel matrix. This probably explains the constant value of Πosm in degrading dex-
HEMA gels (Figure 5): during degradation, the amount of free dextran chains in the dex-
HEMA gels increases, however, they do not increase the osmotic pressure as they behave 
as additional network chains in the remaining dex-HEMA network.  
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Figure 7.  Osmotic pressure of a non-degraded dex-HEMA gel (DS2.9; 25%) and a 
similar dex-HEMA/dextran gel containing 12.5% dex-HEMA (DS2.9) and 12.5% dextran.  
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Besides the differences in shape of the swelling pressure curves (Figures 4 and 6), 
the maximal value Πsw (which is obtained at complete degradation) significantly differs 
between dex-HEMA and dex-MA/dextranase gels. This is explained as follows. The 
molecular weight of the dextran chains(being the degradation products in the dex-HEMA 
gels) is much higher than the molecular weight of the oligosaccharides (being the 
degradation products of dex-MA/dextranase gels). Consequently, for dex-HEMA gels and 
dex-MA gels with the same initial (respectively dex-HEMA and dex-MA) concentration at 
cross-linking, the molar concentration of the degradation products is much higher in the 
solution obtained by degrading dex-MA gels than in the solution obtained from dex-
HEMA gels. 
 As explained above, for dex-MA/dextranase gels the swelling profile in Figure 
2C does not follow the swelling pressure in Figure 4. Although, for dex-HEMA gels the 
swelling profile (Figure 2F) does resemble the swelling pressure profile (Figure 6). One 
could wonder, however, why the sudden increase in swelling pressure is not reflected in a 
sudden volume expansion of the gel. This is explained by the fact that the increase in 
swelling pressure occurs at the very end of the degradation process i.e. when the gel 
becomes a solution. At this time  swelling measurements are no longer feasible. 
 
 
CONCLUSIONS 
 
This study compares the behavior of dextran-based hydrogels that degrade 
through different mechanisms. On the one hand dex-MA hydrogels that are degraded by 
entrapped dextranase were used, being a model for hydrogels that degrade by hydrolysis 
of the polymer backbone. On the other hand, dex-HEMA hydrogels were studied, as a 
model for hydrogels that degrade by hydroysis of the cross-links. Upon degradation of 
dex-MA/dextranase gels the degradation products, being oligosaccahrides, were gradually 
released from the gels, an exponential decrease in G’ and a minor increase in swelling was 
observed. In degrading dex-HEMA gels the release of degradation products, being dextran 
chains, only began after an initial lag phase, followed by a rather fast release of 
degradation products. A higher swelling was observed for degrading dex-HEMA gels 
compared to dex-MA/dextranase with the same dextran concentration.   
The main focus of this study was to investigate the swelling pressure profile of 
the degrading dextran gels and to show how the degradation mechanism influences the 
change in swelling pressure. Typically, for dex-MA/dextranase gels a gradual increase in 
swelling pressure profile was observed. For dex-HEMA gels a sudden increase in swelling 
pressure at the end of the degradation occured, an interesting feature to use dex-HEMA 
gels as core in the exploding microcapsules outlined in the introduction. From the release 
of the degradation products and the elasticity of the degrading dex-MA/dextranase gels the 
swelling pressure was also calculated and seemed to be in good agreement with the 
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experimentally measured values. This allowed to conclude that the swelling pressure of 
degrading dex-MA/dextranase gels can be well predicted from their osmotic pressure, as 
calculated from the release studies. In other words, the increase in swelling pressure in 
degrading dex-MA/dextranse gels is (nearly) completely governed by the increase in 
osmotic pressure. However, in the initial period of the degradation the increase in swelling 
pressure of the dex-HEMA gels seemed to be completely attributed to the decrease in 
elasticity as we observed minor changes in osmotic pressure in that period.  
Finally, the maximal swelling pressure which can be obtained by degrading the 
gels equals the osmotic pressure of the corresponding solution of degradation products. 
Consequently, as the degradation products are oligosaccharides in dex-MA/dextranase 
gels while they are dextran chains in dex-HEMA gels, this maximal value of the swelling 
pressure is higher for dex-MA/dextranase gels than for dex-HEMA gels with the same 
dextran concentration at cross-linking. 
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Abstract 
Self-exploding microparticles show potential for advanced delivery 
of certain therapeutics. This study evaluates (i) whether degrading dextran 
hydroxyethyl methacrylate (dex-HEMA) microgels can become coated by 
a lipid membrane and (ii) whether the surrounding membrane can be 
suddenly ruptured by the increasing swelling pressure of the degrading 
microgel. We found that adsorption of charged liposomes to oppositely 
charged microgels allows efficient coating of the microgels; microparticles 
with a ‘core-shell’ structure were clearly obtained. Especially, we could 
experimentally confirm that the swelling pressure increase in degrading 
dex-HEMA microgels can suddenly destroy its surrounding lipid 
membrane. As no external trigger is needed to rupture the membrane ‘self-
exploding’ microparticles were obtained in this way. 
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INTRODUCTION 
 
Pharmaceutical research strives to design systems that deliver drugs according to 
therapeutic needs. Conventional drug delivery systems release the drug in a rather fast 
way. This results in a sharp increase in drug concentration in the blood. After peaking the 
drug concentration often decreases so fast that the time spent in the therapeutic 
concentration range is relatively short. To overcome this and to avoid multiple dosing, 
controlled drug delivery scientists designed tablets, pumps, implants, patches, ... which 
provide a continuous drug release over a prolonged period of time. However, there are 
many applications in medicine where a non-uniform release profile would be more 
beneficial.1 For bioactive agents such as hormones (e.g. growth hormones) many have 
suggested that pulsed release may offer advantages over continuous release.2-4 Also, a 
pulsed release pattern could be advantageous for drugs that develop biological tolerance 
and for drugs that require dosing at night. Devices that give pulses of drugs at well-
defined times after injection could be used to provide ‘single-shot’ vaccines. Such devices 
could improve vaccination coverage by reducing the number of administrations required 
to generate immunity.  
Very challenging and promising towards multiple pulsed drug delivery from a 
single implant are the biodegradable polymeric chips under investigation by Langer and 
co-workers.5,6 These are poly(lacticglycolic acid) (PLGA) based chips which consist of 
multiple reservoirs loaded with the drug to be released.  Each reservoir is sealed with a 
PLGA degradable membrane, the molar mass of the PLGA controlling the degradation 
rate and thus the time at which the drug is released. It has been shown ‘in vitro’ that such 
devices allow multiple pulsed delivery, even over a period of several months. However, 
the proposed  chips are relatively large (around 1 cm in diameter and 0.5 mm thick) and 
have to be implanted. Injectable (micron sized) devices which could deliver the drug at a 
programmed time after injection could make a further step in multiple pulsed drug 
delivery.   
It is well known that secretory granules are very efficient in storage and sudden 
delivery of molecules like e.g. histamine, serotonin, calcium, ...7,8 Such nano-/microscopic 
granules consist of a polyanionic biopolymer matrix surrounded by a lipid membrane that 
prevents the leakage of the entrapped molecules.  Release of the stored molecules requires 
electrochemically stimulated fusion of the granule's membrane with the cell membrane. 
Hereby small pores are formed through which ions (sodium, potassium from the 
extracellular matrix) and water can enter the granule. These ions exchange with the stored 
molecules, swelling of the matrix occurs which results in a rapid release of the molecules 
through the pores to the extracellular matrix. The secretory granule concept has inspired 
many scientists. E.g. Kiser et al. proposed a combination of microgel science and lipid 
chemistry to mimick secretory granules for drug delivery.9,10 They designed (negatively 
charged) methacrylic acid based microgels, coated by a lipid bi-layer, which were loaded 
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with the anticancer drug doxorubicin. Pulsed doxorubicin release was indeed observed 
upon punching holes in the lipid membrane by electroporation. This way of triggering 
may be however difficult to realize ‘in vivo’. The attractive concept of Kiser et al. 
encouraged us to try to design 'self-exploding microparticles' which could store a drug for 
a desired period and could rapidly release at a certain time without an external stimulus. In 
such a ‘programmed’ device the release would be completely governed by the inner 
mechanism of the device.  
For this purpose we envisioned micron sized (bio)degradable dextran based gel 
particles surrounded by a membrane which is permeable to water but impermeable to both 
the entrapped drugs and the osmotic agents (i.e. the degradation products of the microgel). 
As membranes lipids10-13, polymers14 and polyelectrolytes15 can be used. However, in this 
study the dextran based microgels are coated with lipid vesicles. Lipid vesicles have been 
widely used as models for biological membranes to study permeation, to study lipid 
protein interactions, … 16-18 As biomembranes are also supported by a polymer network 
(i.e. the cytoskeleton), our lipid coated microgels are closely related. Pulsed drug release 
can be obtained as follows from the ‘self-exploding microparticles’. After injection, the 
microgel degrades and its swelling pressure will increase, once high enough, the internal 
pressure will suddenly rupture the membrane causing an immediate release of the 
entrapped drugs. The inner mechanism which governs the swelling pressure increase, and 
thus the time of explosion of the microcapsules, is the degradation rate of the microgel.  
Several attempts have been made to coat hydrogels with lipids. Kiser et al. 
sedimented (by centrifugation) drug loaded microgels to a dried lipid film. A very low 
coatings efficiency was obtained. However, coated and non-coated particles could be 
separated.9,10 Ng et al.  modified the hydrogel surface by inserting lipid anchors at the 
microgel surface, which promote the self assembly of lipid membranes.11,12 Kazakov et al. 
made liposomes which where loaded with monomers using sonification. Afterwards 
gelation was performed with photo-polymerization.19 All these techniques have several 
drawbacks, such a s low yield and stability, inhomogeneous coating or not applicable to 
hydrogel microspheres with a diameter in the range of 1 to 10 µm. De Geest at al. recently 
proved the use of polyelectrolyte coating of hydrogels by using the layer-by-layer 
technique.15 Lipid coating based upon electrostatic interactions of oppositely charged 
microgels and lipids has been proposed as alternative lipid coating technique. 
In this study we aimed to prove that 'self-exploding core-shell microparticles’ can 
be designed in which the membrane (made from lipids) can be disrupted by the increasing 
swelling pressure of the degrading gel core (based on dextran hydroxyethylmethacrylate 
(dex-HEMA)). Clearly, the tensile strength and permeability of the membrane (which 
depends on the thickness of the coating and the chemistry of the building blocks) and the 
osmotic properties of the gel core (that change during degradation and which depend on 
the polymer composition and the degree of cross-linking) need to be fine tuned.  
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EXPERIMENTAL SECTION 
 
Synthesis of dex-HEMA 
 
Dex-HEMA was prepared and characterized according to a method described 
elsewhere.20 Dextran with a number average molecular weight (Mn) of 19 000 g/mol was 
used. The degree of substitution (DS i.e. the number of HEMA groups per 100 
glucopyranose residues in dextran) was determined21 by proton nuclear resonance 
spectroscopy in D2O with a Gemini 300 spectrometer (Varian). The DS of the dex-HEMA 
used in this study was 2,5. 
 
Preparation of the microgels 
 
Dex-HEMA microgels were prepared according to Stenekes et al.22 In detail, 
deoxygenated aqueous solutions of dex-HEMA (25% w/w solution) and polyethylene 
glycol (PEG; 24% w/w solution; Mw 20 000 g/mol) were prepared. The dex-HEMA and 
PEG solutions were vigorously mixed with a vortex for 1 min under a nitrogen 
atmosphere to obtain a water-in-water emulsion. A PEG/dex-HEMA ratio of 40 (v/v) was 
used; the total volume amounted to 5 mL. The resulting emulsion was allowed to stabilize 
for 10-15 min. Subsequently TEMED (100 µl; pH neutralized with 4 N HCl) and KPS 
(180 µl of 41 mM) were added to cross-link the dex-HEMA. After gentle mixing the 
emulsion was incubated without stirring for 30 min at 25°C yielding microgels with an 
estimated water content of 75% (w/w).23 Three washing and centrifugation steps with 50 
mL Milli-Q water removed the residual KPS and TEMED. The remaining pellet was 
suspended in 5 mL phosphate buffer (10 mM at pH of 7.0).  
To prepare respectively negatively and positively charged dex-HEMA microgels 
24, respectively methacrylic acid (MAA; 25µl) or dimethyl aminoethyl methacrylate 
(DMAEMA; 35µl) was added to the PEG/dex-HEMA mixture described above, just 
before vortexing it. Figure 1 shows the chemical structure of MAA and DMAEMA, 
respectively. In this chapter “dex-HEMA-MAA microgels” and ‘dex-HEMA-DMAEMA 
microgels” refer to respectively negatively charged and positively charged microgels. 
To prepare fluorescent microgels 4 mg/mL tetramethyl rhodamine B 
isothiocyanate (TRITC) labeled dextran (Mw of 158 000 g/mol) was added to the dex-
HEMA solution used in the preparation of the microgels. 
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Figure 1. Chemical structure of MAA (A) and DMAEMA (B) 
 
Size distribution of the microgels 
 
The size distribution of the microgels was analyzed by both laser diffraction 
(Mastersizer, Malvern Instruments) and a transmission light microscope (Eclipse TE300D, 
Nikon).  Home made imaging software was used. 
 
 
Preparation of the lipid vesicles  
  
Lipid vesicles (liposomes) were prepared as follows. First the lipids were 
dissolved in chloroform. The chloroform was evaporated at room temperature using 
nitrogen and  the lipid film was further dried under vacuum for 12 hours to remove any 
remaining chloroform. Large multi-lamellar vesicles were obtained by hydration of the 
dry lipid film with a carboxyfluorescein (CF) solution (100 mM CF (Fluka), 0.95 M NaCl 
in 50 mM HEPES at pH of 7.4; 2180 milliosmole (mOsm)) up to a final lipid 
concentration of 5 mg/mL. Uni-lamellar vesicles were then obtained by extruding the 
sample eleven times through two stacked polycarbonate filters (100 nm pore size, 
Nucleopore) using an extruder (Avanti Polar Lipids). The size distribution of the vesicles 
 86
CHAPTER 6 
was determined by dynamic light scattering (Autosizer 4700, Malvern Instruments).  
Different lipid compositions were used: (i) dioleoyl phosphatidylcholine (DOPC) and 
cholesterol (CHOL) (molar ratio’s 10:0, 9:1, 7:3 and 5:5); (ii) stearoyloleyl 
phosphatidylcholine (SOPC) and dioleoyl trimethylammonium propane (DOTAP) (molar 
ratio’s 9:1, 7:3 and 5:5); (iii) SOPC and dioleoyl glycerophosphate (DOPA) (molar ratio 
9:1) and (iv) SOPC:DOPA:CHOL (molar ratio 4:1:5). All lipids were from Avanti Polar 
Lipids. After extrusion the unentrapped CF was removed by passing the sample down a 
Sephadex G-50 column (1.5 × 10 cm) equilibrated with a solution with the same osmotic 
activity as the CF solution inside the lipid vesicles (i.e. 2180 mOsm).  
 
Osmotically induced lysis of lipid vesicles 
 
Osmotically induced lysis of the lipid vesicles was studied by monitoring the 
release of the entrapped carboxy fluorescein.25,26 In the vesicles the fluorescence of the 
highly concentrated CF is quenched. Only upon release of CF from the vesicles the CF 
molecules become fluorescent. The vesicles were diluted into buffered saline solutions 
(i.e. dilutions of 1,1 M NaCl, 50 mM HEPES at pH of 7.4) of different osmotic activities 
as determined from freezing point depression using an Advanced® Micro-osmometer 
(Model 3300, Advanced Instruments). Standards of known osmotic activity (50, 290 and 
850 mOsm) were also analyzed. The lysis experiments occurred at 25°C. The fluorescence 
was monitored 1 min after submerging the lipid vesicles in the saline solutions (λex 488 
nm; λem 520 nm; Aminco Bowman® Luminescence  Spectrometer). Complete CF release 
was achieved by adding 10 µL Triton X-100 (100 mM) to the sample.  
 
Lipid coating of the dex-HEMA and dex-MA microgels 
 
Lipid vesicles were prepared as described above. The lipid film was hydrated by 
adding Milli-Q water (final lipid concentration of 1 mg/mL) and sonicated (Bransonic 32, 
Branson Ultrasonics, 150 Watt) for 5 min. The lipid compositions used to coat the 
microgels were similar to the ones described above. A small amount (0.05 mol% of the 
total lipid) of the lipid soluble fluorescent dye cholesteryl BODIPY-FL C12 (λex 504 nm; 
λem 511 nm; Molecular Probes) was added to make the lipid coating fluorescent. 
The (charged) lipid vesicles (500 µL) were mixed with a suspension (200 µL) of 
(oppositely charged) microgels and incubated for 20 min to allow adsorption of the lipid 
vesicles to the surface of the microgels. Then the samples were centrifuged (Microfuge 18 
Centrifuge, Coulter Beckman) for 5 min at 500 g and the supernatant was removed. The 
centrifugation and resuspension procedure was repeated three times. 
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Confocal laser scanning microscopy 
 
Confocal micrographs of the lipid coated microgels were taken with a MRC1024 
Bio-Rad confocal laser scanning microscope equipped with a krypton-argon laser. An 
inverted microscope (Eclipse TE300D, Nikon) was equipped with a water immersion 
objective lens (Plan Apo 60X, NA 1.2, collar rim correction, Nikon).  
 
Electrophoretic mobility 
 
The electrophoretic mobility of the (lipid coated) microgels was measured by 
means of a Malvern Zetasizer 2000 (Malvern Instruments). The ζ-potential was calculated 
from the electrophoretic mobility using the Smoluchowski relation. The dex-HEMA 
microgel dispersion was centrifuged (1 min. at low speed (500 rpm)) and the 
measurements were done on the microgels that remained in the supernatant.  
 
Scanning electron microscopy (SEM) 
 
Scanning electron microscopy (SEM) measurements on (lipid coated) microgels 
were carried out using a Gemini Leo 982 instrument (Digital Scanning Microscope) 
operating at an accelerating voltage of 3 keV.  
    
 
. 
RESULTS & DISCUSSION 
 
Preparation and characterization of dex-HEMA microgels 
 
A wide range of techniques is available for the preparation of microparticles. For 
medical applications it is of paramount importance to produce microparticles under mild 
conditions. As an example, the use of organic solvents (as in the preparation of the well 
studied ploy(lactic acid - co - glycolic acid) (PLGA) microspheres) has to be avoided as it 
may damage e.g. incorporated therapeutic proteins. In this study, the dextran microgels are 
prepared by a water-in-water emulsion technique based on the immiscibility of the PEG 
and dex-HEMA solutions.22,27 As we expected that charged microgels are more suitable 
towards lipid coating than neutral microgels, we prepared positively (dex-HEMA-
DMAEMA) and negatively (dex-HEMA-MAA) charged dex-HEMA microgels. As 
described in the experimental section, MAA (pKa = 4,5) and DMAEMA (pKa = 8,3) were 
used to obtain respectively negatively an positively charged dex-HEMA microgels at 
neutral pH.24 The incorporation of charged groups into the microgels was verified by 
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measuring the ζ-potential of the dex-HEMA microgels. Indeed, a negative ζ-potential was 
observed in case MAA was used, while a positive ζ-potential was measured in case 
DMAEMA used, indicating the successful charge loading of dex-HEMA microgels (data 
are further discussed).  
The size distribution of the dex-HEMA microgels was characterized by 
respectively transmission light microscopy and laser diffraction. The results are shown in 
Figure 2: a number average diameter of 3 µm was obtained by both methods. The rather 
broad size distribution is due to the nature of the water-in-water emulsion technique. 
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Figure 2. Size distribution of the dex-HEMA microgels determined by laser diffraction 
(full line) and transmission light microscopy (with n=650). 
 
Lipid coating of dex-HEMA microgels 
 
As outlined in the introduction, to obtain exploding microparticles, a (water 
permeable) coating which can be ruptured by the swelling pressure of the degrading 
microgel core is necessary. Technologies which allow to coat the surface of hydrogels are 
very attractive in biomedicine and pharmacy. A general method for the coating of 
hydrogel surfaces does, however, not exist so far. Especially, coating hydrogel beads and 
microparticles requires additional precautions when compared to coating planar supports, 
a main issue being that the particles need to remain colloidaly stable. Interesting studies on 
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lipid coating of microgels have been reported in literature.9-11,24,28 Also the method for 
lipid coating of microgels reported by Kiser et al., by sedimentation of the microgels on a 
lipid film by centrifugation, is attractive.9,10 Although, following this method only a few 
percentage of the dex-HEMA microgels became lipid coated.  
Looking for an elegant and efficient way to coat microgels with a (biocompatible) 
lipid membrane we came to the idea to make the dex-HEMA microgels positively or 
negatively charged and to expose them to oppositely charged lipid vesicles (Figure 3). By 
adding DMAEMA, respectively MAA to the PEG/dex-HEMA emulsion we indeed 
obtained positively (dex-HEMA-DMAEMA) respectively negatively (dex-HEMA-MAA) 
charged dex-HEMA microgels, as evidenced from ζ-measurements (Figure 5). The 
microgels were consequently submerged in a dispersion of oppositely charged lipid 
vesicles.29,30 As Figure 4 clearly shows, all the dex-HEMA microgels became lipid coated. 
Microparticles with a core-shell structure were obtained with lipids only at the surface of 
the microgels and not in the interior. As Figure 3 illustrates, we assume that the 
nanoscopic lipid vesicles associate spontaneously with the charges at the microgel surface. 
Once the surface of microgels is covered, the lipid vesicles probably spread open and form 
a lipid bi (or multi)layer.  
 
 
 
 
 
Figure 3. Adsorption of charged lipid vesicles onto oppositely charged dex-HEMA 
microgels. The black dots represent the cross-links in the dex-HEMA microgels. 
 
 
Besides CSLM also electrophoretic mobility measurements proved that the dex-
HEMA gels became coated. As Figure 5 shows, the zeta-potential of negatively and 
positively charged dex-HEMA microgels turns respectively positive and negative upon 
exposing them to the oppositely charged lipid vesicles.  
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Figure 4A. CSLM images of dex-HEMA-MAA microgels coated with SOPC:DOTAP 
(9:1). The core is red as the microgels are fluorescently labeled with TRITC-dextran and 
the coat is green as the lipid layer is labeled with cholesteroyl BODIPY-FL C12. The 
coating procedure seems very efficient as all microgels seems to be lipid coated. B. Red 
and green fluorescence intensity along the line indicated in the lipid coated microgel 
above. 
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Figure 5. ζ-potential of uncoated and lipid coated microgels. A. Negatively charged dex-
HEMA-MAA gels coated with the positively charged lipid SOPC:DOTAP (9:1). B. 
Positively charged dex-HEMA-DMAEMA gels coated with the negatively charged lipid 
SOPC:DOPA (9:1). 
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CLSM does not give any information on the morphology of the (lipid coated) 
microgels, therefore scanning electron microscopy was used to itemize the fine structure 
of the surface of the (non) coated microgels.  Figure 6 despicts SEM images of repectively 
non coated (left image) and coated microgels (right image). It reveals that the surface of 
the uncoated microgels is smoother compared to the surface of the coated microgels.  
 
 
Figure 6. SEM images of uncoated dex-HEMA-MAA microgels  (left) and SOPC:DOTAP 
coated dex-HEMA-MAA microgels (right).  
 
 
Tensile strength of the coating and swelling pressure of the gel core 
 
As described above we coated the dex-HEMA microgels with lipids. One 
argumentation to use lipids is that they are biocompatible and that liposomes are already 
medically used. Another major reason however is that we found out that degrading dex-
HEMA microgels have a reasonable chance to rupture a surrounding lipid coating. These 
findings followed from the considerations below.  
First, we determined the osmotic pressure gradient necessary to rupture the lipid 
vesicles used to coat the dex-HEMA microgels. Therefore, CF containing (uni-lamellar) 
SOPC:DOTAP (9:1) lipid vesicles (100 nm) were bathed in buffered NaCl solutions with 
different osmotic activities. Figure 7 shows the CF release. Little CF is released if the 
osmotic pressure (osmotic activity) gradient is lower than about 1250 mOsm while 
significant CF release occurs at higher osmotic pressure gradients. The intersection with 
the x-axis of the linear fit of the data points with a CF release higher than 10%, estimates 
the average maximum osmotic pressure gradient the lipid vesicles can withstand.25,26,31 
When vesicles are exposed to gradients lower than this value they probably only swell 
causing dilational strains of the membrane which results in a higher membrane tension. At 
the maximal membrane tension elastic behavior terminates in membrane rupture and lysis 
occurs. Clearly, the CF release is not an ‘all-or-nothing’ effect. The reason why the CF 
 92
CHAPTER 6 
release does not occur suddenly at a certain value of the osmotic gradient but gradually 
has been debated by others.26 It is attributed to both the size distribution of the vesicles 
(the smaller vesicles tolerating much greater osmotic pressure gradients than the larger 
vesicles, as predicted by Laplace law) and the so called ‘membrane resealing’ whereby the 
vesicles release only a portion of their content.   
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Figure 7. Release of CF from (uni-lamellar) SOPC:DOTAP (9:1) vesicles (100 nm) 
diluted in NaCl containing buffer solutions. The x-axis represents the osmotic pressure 
gradient being the difference between the osmotic activity of the CF solution in the 
vesicles (‘internal solution’) and the osmotic activity of the NaCl buffered solution 
(‘external solution’). Compared to the internal solution the external solutions are hypo-
osmotic. The y-axis represents the fluorescence of the external solution (100% being the 
fluorescence of the external solution after complete lysis of the vesicles by Triton X-100). 
The measurements were performed in triplicate. 
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Second, knowing the osmotic pressure gradient necessary to rupture the uni-
lamellar SOPC:DOTAP (9:1) lipid membrane of 100 nm vesicles, using Laplace’s law one 
can calculate the tensile strength of the membrane when it ruptures, being the maximal 
tensile strength (τmax) of the membrane: 
 
2max
r×∆= πτ               (1) 
 
where ∆π (N/m2~ mOsm) is the osmotic pressure gradient and r (m) is the radius. For the 
uni-lamellar SOPC:DOTAP (9:1) membrane τmax of 750 N/m was found. Table I 
overviews τmax–values we obtained for neutrally, positively and negatively charged uni-
lamellar membranes made from different lipid compositions. The tensile strengths 
obtained are higher than the tensile strength reported by Needham et al. using the micro-
aspiration technique.32 This might be explained by differences in time course at which the 
experiments are performed. Table I also shows that τmax of DOPC:CHOL vesicles 
increases with increasing cholesterol concentration. This has also been observed and  
explained by others. 32 
Third, assuming dex-HEMA microgels (e.g. 3 µm in diameter)  become coated 
with a uni-lamellar lipid membrane one can consequently calculate (by equation 2) which 
pressure the degrading microgel has to excert to rupture the membrane in case the coated 
microgels are bathed in a solution which is iso-osmotic to the interior of the particles. 
Table I overviews the ‘critical swelling pressure’ (πswell, crit)  necessary to rupture lipid 
coated dex-HEMA microgels of 3 µm in diameter.  
Fourth, πswell, crit is now compared with the increase in swelling pressure of dex-
HEMA gels when they degrade. Dex-HEMA hydrogels degrade through hydrolysis of the 
carbonate ester bounds in the HEMA based crosslinks. Hydrolysis results in high 
molecular weight dextran chains (Mn of 19 000 g/mol) and poly-HEMA fragments (with 
an estimated Mn of 1300 g/mol); when totally degraded dex-HEMA gels become a dextran 
solution. In previous research we focused on the change in swelling pressure of degrading 
(neutral) dex-HEMA gels. A remarkable profile of the swelling pressure upon degradation 
was obtained for the dex-HEMA hydrogels. Apparently, after an initial phase in which the 
swelling pressure raised slightly, a steep increase in swelling pressure was obtained at the 
end of the degradation.33,34 The degradation time in physiological conditions of the dex-
HEMA gels can be tailored by both the degree of substitution and the concentration and 
can be tuned from days to several weeks. The maximal swelling pressure which can be 
reached upon hydrogel degradation is only determined by the initial dex-HEMA 
concentration. Table II shows the maximal swelling pressure which arises through 
degradation of different types of dex-HEMA gels. Comparing these values with πswell, crit 
(Table I) suggests that the lipid membrane surrounding 3 µm sized dex-HEMA microgels 
may become ruptured by the degrading dex-HEMA gel core.   
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Tabel I. Charge, maximal tensile strength (τmax) and critical swelling pressure (Πswell,crit) of 
lipid membranes with different compositions. τmax being the maximal tensile strength the 
membrane can withstand. Πswell,crit being the osmotic pressure difference necessary to 
lyse the lipid membrane of 3 µm sized lipid coated microgels. 
 Lipid composition Molar ratio charge τmax (102. N/m) Πswell,crit (kPa) 
DOPC:CHOL 10 :0 0 6,8 ±  0,1 91 ± 1 
DOPC:CHOL 9:1 0 7.0 ±  0,0 93 ± 1 
DOPC:CHOL 7:3 0 8,5 ±  0,1 113 ± 1 
DOPC:CHOL 5:5 0 9,1 ±  0,2 121 ± 2 
SOPC:DOTAP 9:1 + 7,5 ± 0,0 101 ± 0 
SOPC:DOTAP 7:3 + 7,8 ± 0,1 103 ± 1 
SOPC:DOTAP 5:5 + 6,4 ± 0,0 86 ± 1 
SOPC:DOPA 9:1 - 6,5 ± 0,1 86 ± 1 
SOPC:DOPA:CHOL 10:1:4 - 6,5 ±  0,3 87 ± 5 
 
 
Tabel II. Swelling pressure of different dex-HEMA hydrogel compositions at 25°C (see 
Figure 6 of Chapter 3) 
Dex-HEMA hydrogel type Swelling pressure (kPa) 
DS 2.9; 25% 114 ± 3 
DS 2.9; 30% 161 ± 3 
DS 5.0; 20% 76 ± 2 
DS 7.5; 20% 76 ± 2 
 
 
Self-explosion of core-shell microparticles 
 
We further examined the behavior of the lipid coating during and after complete 
degradation of the microgel core. As lipid membranes are known to have limited 
permeability, we expected that the degradation products of the dex-HEMA microgels (i.e. 
dextran chains Mn of 19 000 g/mol) would not leave trough the lipid membrane. 
Depending on the composition, complete degradation of dex-HEMA gels ranges from 
days to weeks, as explained above. To accelerate the degradation we submerged the lipid 
coated dex-HEMA microgels in an alkaline solution and followed them in time by CLSM 
(Figure 8). The microgels first swoll moderately; At a given moment a huge volume 
expansion occurred followed by a destruction of the lipid coating. The lag-time in 
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swelling of the coated microgels was somehow in agreement with the lag-time in swelling 
pressure we observed earlier for degrading dex-HEMA gel slabs.33,34 As a ‘negative 
control’ we also followed the behavior in time of non-coated dex-HEMA microgels. The 
picture was totally different: the microgels seemed to dissolve gradually in the alkaline 
solution (data not shown as clear images of the microparticles could not be obtained 
during the degradation experiment).       
 
 
     degradation time 
 
 
 
 
 
 
 
 
  
 
Figure 8. CLSM images of SOPC:DOTAP (9:1) coated dex-HEMA-MAA microgels 
bathed in an alkaline solution. Snapshots were taken every 15 sec. In some particles 
localized areas of expansion at the surface of the microgels were visible. Possibly due to 
heterogenieties in the lipid coating certain areas of the microgel seemed to swell stronger 
before the entire particle explodes. Similar observations were seen by Kraft et al. on lipid 
coated microgels exposed to detergents.35  
 
To prove that the alkaline solution did not damage the lipid membrane we 
prepared lipid coated (SOPC:DOTAP (9:1)) dextran-methacrylate (dex-MA) hydrogels 
containing MAA. While dex-HEMA hydrogels degrade through hydrolysis, dex-MA gels 
do not as carbonate esters are not present in the cross-links. Non-coated dex-MA gels were 
stable in alkaline solutions and did not swell. Also, lipid coated dex-MA-MAA microgels 
bathed in alkaline solution did not swell while the lipid coating remained intact (data not 
shown). This allowed us to conclude that the rupture of the membrane in the lipid coated 
dex-HEMA microgels is attributed to the increase in swelling pressure of the degrading 
hydrogel core.  
 
 
CONCLUSIONS 
 
This study shows that charged dex-HEMA microgels can become lipid coated by 
electrostatic interaction with oppositely charged lipid vesicles. From CLSM experiments 
we concluded that microparticles with a ‘core-shell’ structure were obtained. Especially, 
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the coating method seemed to be very efficient as all dex-HEMA microgels became 
surrounded by a lipid membrane. SEM measurements revealed a rougher surface of the 
coated microgels compared with he surface of non-coated microgels. The maximal tensile 
strength lipid membranes can withstand (τmax) was further determined.  From τmax we 
calculated the swelling pressure the gel core (assuming 3 µm in diameter) needs to rupture 
its surrounding lipid coating. These calculations showed evidence that rupturing the lipid 
membrane by the degrading microgels  should be possible. Indeed, ‘explosion’ of the lipid 
coating could be confirmed experimentally.   
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SUMMARY 
 
Pharmaceutical research strives to design drug delivery systems that respond to 
therapeutic needs. Because of rhythms in physiological parameters and pathological 
conditions (e.g. asthma, angina pectoris), the conventional paradigm concerning drug 
concentrations “the flatter the better” may not be what the organism may need. Instead, to 
correlate with our biological needs, 'precisely timed drug delivery', which can be 
accomplished with ‘programmable dosage forms’, is required. Precisely timed drug 
delivery may maximize therapeutic efficacy, may minimize dose frequency and may 
reduce toxicity by avoiding side effects and drug tolerance. It was our intention to use 
hydrogels from (hydroxyethyl) methacrylated dextrans (dex-(HE)MA) in this study for 
creating such a programmed dosage form.  Concepts proposed to release drugs in a pulsed 
manner from ‘programmed polymeric pharmaceutical devices’ were reviewed. The 
devices were classified based on the physicochemical and biological principles that trigger 
the release: (i) pulsed delivery by degradation of the device (like spontaneous hydrolysis 
and enzymatic degradation) (ii) pulsed delivery by osmotic pressure of the device (i.e. by 
osmotic pumping and by osmotic bursting) and (iii) pulsed delivery by the combination of 
degradation and osmotic bursting of the device. In the last part of the literature overview 
our concept of ‘exploding coated microspheres’, consisting of a degradable hydrogel core 
and a semi-permeable membrane is introduced [see Figure 1, Chapter 3]. The membrane 
is only permeable to water and not permeable to the entrapped drugs or osmotic agents.  
However, after drug administration by injection (simulated in vitro by immersion in 
buffer), water permeates through the membrane in the hydrogel containing the drug, the 
hydrogel core degrades and the internal osmotic pressure of the membrane surrounded 
hydrogel rises until the membrane is ruptured. At that moment, after a well defined lag-
time, the drugs are liberated from the hydrogel core. The combination of different types of 
degradable coated microgels could be of particular use in e.g. ‘single shot vaccination’ in 
which the initial and subsequent booster release of antigens could be obtained in one 
single injection. The general aim of this study was to design ‘exploding coated 
microspheres’ as pulsed delivery system by using membrane surrounded hydrogels. As 
core material dextran based hydrogels were used. As membrane we especially focused on 
lipids. In order to identify the key parameters that influence the bursting of the semi-
permeable membrane and drug release, it was decided to study two main aspects:  (i) the 
thermodynamic properties of the degrading hydrogels (such as the above described 
hydrogels) and (ii) the mechanical properties of the membrane (such as lipids). 
 
The thermodynamic properties include the swelling pressure (Πsw) of the hydrogel 
which is described as the sum of two terms: an osmotic pressure (Πosm) expanding the 
network, and an elastic pressure (Πel) acting against expansion. Since membrane 
surrounded degrading hydrogels develop a pressure as a function of time, it was likely that 
these properties somehow correlated with the rupture of the membrane followed by drug 
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release. Therefore, an in depth analysis of the thermodynamic properties of the hydrogels 
was performed, to gather enough information to describe the evolution of the swelling 
pressure during hydrogel degradation.   
Because hardly any references were found dealing with swelling pressures of 
(degrading) hydrogels, a methodology was developed.  This method based upon osmotic 
deswelling, allowed measuring the swelling pressure of degrading and non-degrading dex-
HEMA hydrogels. It is found that the degradation rate strongly depends on the initial dex-
HEMA concentration and degree of substitution (DS , number of hydroxyethyl 
methacrylates per 100 glucopyranose residues). The variation of the swelling pressure at 
each stage of degradation could be satisfactorily described by the equation Πsw = A(ϕn–
ϕe,tn-1/3ϕ1/3), where ϕe,t is the concentration of the fully swollen gel at degradation time t, 
and A and n are constants. A remarkable profile of the swelling pressure upon degradation 
was obtained for the dex-HEMA hydrogels [see Figure 2B, Chapter 3]: apparently, after 
an initial phase in which the swelling pressure raised slightly, a steep increase of the 
swelling pressure was obtained at the end of the degradation. The slight changes in 
swelling pressure during the first 15 days of degradation is caused by the decrease of the 
elastic pressure. The end of the degradation is accompanied by the release of a major 
amount of dextran chains. The sudden increase in swelling pressure at the end of the 
degradation can be explained by the fact that only at the end of the degradation (close to 
the gel-sol transition) the free dextran chains contribute to the osmotic pressure. Before 
the dextran chains behave as additional polymer network chains and remain physically 
entrapped.  
 We wondered whether we could confirm the remarkable swelling pressure profiles 
of the degrading dex-HEMA gels by using dex-HEMA gels containing different amounts 
of free dextran. It was concluded that dex-HEMA gels made in the presence of known 
amount of free dextran chains exhibit osmotic properties similar to those of the partially 
degraded dex-HEMA gels [see Figure 4, Chapter 3]. To develop degradation controlled 
exploding microspheres as platform for pulsed drug delivery, it was desirable to design 
hydrogels that possess different degradation kinetics. Swelling pressure versus 
degradation time plots were obtained from the swelling pressure measurements of dex-
HEMA/dextran gels in conjunction with dextran release data of degrading dex-HEMA 
gels. The swelling pressure profiles indicate that the profile strongly depends on the 
concentration of the cross-linked dex-HEMA and its degree of substitution [see Figure 6, 
Chapter 3]. The initial value of the elastic modulus, the height of the ‘plateau’ region of 
the osmotic pressure plot and the maximal reachable swelling pressure increase with 
increasing dex-HEMA concentration. The DS increases the amount of possible cross-links 
which is reflected in the increased elastic modulus. Generally increasing the cross-link 
density (due to increasing ether DS or dex-HEMA concentration) lengthens the 
degradation time and, consequently, the time required to attain a certain swelling pressure.  
Because the osmotic deswelling method developed in Chapter 2 is very time and 
product consuming, an osmometer was developed for the charaterization of the 
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thermodynamic properties of degrading hydrogels [see Figure 2, Chapter 4]. Degradation 
induced changes in the osmotic swelling pressure of pharmaceutical hydrogels are 
measured by confining the hydrogel in an enclosure between a rigid semi-permeable 
membrane and the diaphragm of a pressure transducer. Sensor response time ranged 
between 3 and 6 hours for polymer solutions and polymer hydrogels respectively. The 
device was validated by measurement the pressure of dextran and PEG solutions with 
known osmotic pressure. The pressure values were in good agreement with literature data. 
In order to further validate the device the swelling pressure of a dex-MA (DS3.1; 25%) 
hydrogels was measured and compared with osmotic deswelling data of the same gel. It 
takes about 64 ± 10 kPa of mechanical pressure and 69 kPa of osmotic stress to keep the 
hydrogel volume fixed. Therefore both methods are considered to be in acceptable 
agreement. The device is able to monitor constant changes in osmotic properties of the 
enzymatic degrading hydrogel, i.e. dex-MA/dextranase gel. However, degradation of the 
dex-HEMA gels was inhibited inside the device and changes in osmotic properties could 
not be followed. In conclusion, depending on the type of hydrogel system and depending 
on its degradation mechanism the home-made osmometer is a suitable alternative for the 
osmotic deswelling technique.   
  
Having established good methods for evaluation of the swelling pressure of 
degrading hydrogels, the influence of the degradation mechanism on the swelling pressure 
was analysed in more detail. A hydrogel can be bulk degraded by two different 
mechanisms: by a degradation of the polymer backbone or by a degradation of the cross-
links.  As a model for hydrogels which are degraded at the polymer backbone, dex-MA 
hydrogels with incorporated dextranase (dex-MA/dextranase hydrogels), which 
hydrolyses the dex-MA chains, were used.  The degradation of hydrogels at the cross-links 
was studied using dextran hydroxyethyl methacrylate (dex-HEMA) hydrogels. The elastic 
moduli, the release of the degradation products, the swelling and swelling pressure of the 
degrading dextran-based hydrogels were measured. The release of degradation products, 
being oligosaccharides in dex-MA/dextranase gels and dextran chains in dex-HEMA gels, 
and especially the swelling pressure profile seems to be strongly dependent on the 
degradation mechanism of the gels. In case the dextran gels are degraded at their backbone 
the swelling pressure increases rather continuously [see Figure 4, Chapter 5], in case they 
are degraded at the cross-links it increases more discontinuously as a sudden increase 
occurs when the gels are (nearly) completely degraded. This study reveals that the increase 
in swelling pressure in degrading dex-MA/dextranse gels is (nearly) completely attributed 
to an increase in osmotic pressure. However, in degrading dex-HEMA gels the increasing 
swelling pressure seems to be attributed to the decrease in elastic pressure (i.e. elasticity) 
of the gels. Indeed, during a substantial period the osmotic pressure of degrading dex-
HEMA gels does not change. At complete degradation the swelling pressure equals the 
osmotic pressure of the solution of degradation products which is much higher when the 
gels are degraded at their backbone than when they are degraded at their cross-links.    
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Using this steep increase in swelling pressure of degrading dex-HEMA gels to 
rupture a membrane is ideal because it restricts the broadening of the release pattern due to 
size distributions of the microgels and inhomogenities in the surrounding membrane. 
These effects would dramatically influence the release pattern when for example a gradual 
increase of swelling pressure would occur as is the case for the dex-MA/dextranase 
hydrogels.  
The mechanical properties of the membrane surrounding the hydrogel core was 
chosen as second key aspect in this work, since it also determines possibility of rupture of 
the membrane. Therefore, it was wondered which membrane should be used in order to 
obtain a unique membrane surrounded hydrogel delivery system which is able to release 
drugs due to osmotic bursting of the membrane due to hydrogel degradation. Lipids were 
chosen to construct the membrane due to their similarity with natural membranes, which 
have the ideal properties for our proposed pulsed delivery system (i.e. highly water 
permeable and restricted permeability for drugs and hydrogel degradation products). We 
measured the tensile strength by following the carboxyfluorescein released from different 
lipid vesicles due to osmotic induced lysis. Using the law of Laplace, the internal pressure 
needed to rupture 3 µm lipo-beads ranged between 85 and 120 kPa. As a swelling pressure 
from 75-150 kPa can be reached by degrading dex-HEMA gels, it is concluded that the 
hydrogels should theoretically be able to rupture the lipid membrane. Lipid coating of 
hydrogels is not straightforward. We used respectively positively and negatively charged 
gels by adding DMAEMA or MAA during gelation and oppositely charged lipids (i.e. 
SOPC:DOPA and SOPC:DOTAP). By using electrostatic interaction between the 
oppositely charged gel and membrane we obtained a nice core-shell structure and a yield 
of 100% lipid coated microgels [see Figure 4, Chapter 6]. The coating of the microgels 
was evidenced by measuring the electrophoretic mobility, confocal laser scanning 
microscopy and scanning electron microscopy. Finally, as cherry on the pie, the proof of 
principle is given. Exploding coated microspheres i.e. lipo-beads exist [see Figure 8, 
Chapter 6]! To visualize the degradation we observed with CLSM the behavior of the 
coated and non-coated microgels when they were added to a solution of NaOH. In both 
cases the microgels started to swell moderately and at a given moment this swelling 
accelerated. In case of non-coated microgels, they dissolve completely and no traces 
remain. In case of coated microgels, the swelling of continues and at a sudden moment an 
explosion of the surrounding lipid membrane occurs, leading to the release of the 
encapsulated material. By using lipid coated non-degradable dex-MA-DMAEMA 
microgels, it was proven that the NaOH did not damaged the lipid membrane and that the 
bursting of the lipo-beads indeed was caused by the increased internal pressure due to 
microgel degradation. 
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Farmaceutisch onderzoek streeft ernaar om formulaties te ontwikkelen met een 
geneesmiddelen vrijstelling die voldoet aan de therapeutische noden. Door fluctuaties in 
fysiologische parameters en pathologische condities (zoals astma en angina pectoris) kan 
het zijn dat de gebruikelijke doseringsschema’s waarbij een constante geneesmiddelen 
concentratie beoogt wordt gedurende een bepaalde tijd niet echt voldoet aan de noden van 
ons lichaam. Om te voldoen aan onze biologische noden kan tijdsgecontroleerde 
geneesmiddelen vrijstelling met behulp van specifieke formulaties noodzakelijk zijn. 
Voordelen van gepulseerde geneesmiddelen vrijgave zijn: (i) verhoogde therapeutische 
efficiëntie, (ii) verlaagde doseringsfrequentie en (iii) verlaagde toxiciteit door 
neveneffecten en geneesmiddelen tolerantie te vermijden.  
In deze thesis was het onze bedoeling om hydrogelen van (hydroxyethyl) 
gemethacryleerd dextraan (dex-(HE)MA) te bestuderen met het oog op de ontwikkeling 
van een dergelijke formulatie voor tijdsgecontroleerde geneesmiddelen vrijgave. Een 
literatuur overzicht in verband met geneesmiddelen vrijstelling uit ‘farmaceutische 
geprogrammeerde formulaties op basis van polymeren’ werd gegeven. De verschillende 
formulaties werden als volgt geklasseerd: (i) gepulseerde vrijstelling door de afbraak van 
de matrix (zowel hydrolytisch als enzymatisch); (ii) gepulseerde vrijstelling door het 
ontstaan van een inwendige osmotische druk en (iii) gepulseerde vrijstelling door de 
combinatie van enerzijds afbraak van de matrix en anderzijds osmotische vernietiging van 
de formulatie. Op het einde van het literatuur overzicht werd ons concept van 
‘exploderende micropartikels’ geïntroduceerd [zie Figure 1, Chapter 3]. Exploderende 
micropartikels bestaan uit een degraderende hydrogel kern die omgeven wordt door een 
semi-permeabele membaan. Deze membraan is enkel doorgankelijk voor water en niet 
voor de ingesloten geneesmiddelen en de osmotische agentia (namelijk de 
afbraakproducten). Na injectie van de gecoate microsferen (gesimuleerd in vitro door 
immersie in buffer), diffundeert het water doorheen de semi-permeabele membraan. 
Daardoor degradeert de geneesmiddelen bevattende hydrogel kern en ontstaat er een 
inwendige osmotische druk in de kern. Wanneer de inwendige osmotische druk groter 
wordt dan de treksterkte van de membraan, zal de membraan barsten (exploderen). Op dat 
ogenblik zullen de geneesmiddelen vrijgesteld worden. Injectie van meerdere 
exploderende microsferen met verschillende degradatie karakteristieken lijken ideaal voor 
vele toepassingen zoals bijvoorbeeld éénmalige vaccinatie, waarbij zowel de initiële als de 
booster vrijstelling gelijktijdig geïnjecteerd wordt. Het was dan ook de algemene 
doelstelling van dit werk om door middel van een gecoate hydrogel een exploderend 
partikel te ontwikkelen, die in staat is zijn geneesmiddelen op een gepulseerde manier vrij 
te stellen. Dextraan hydrogelen werden bestudeerd als kern materiaal. Als membraan ging 
onze aandacht uit naar lipiden omwille van hun verwantschap met de celmembraan. Om 
inzicht te krijgen in de parameters die het barsten van de membraan en bijhorende 
geneesmiddelen vrijstelling veroorzaken, werd gekozen om het onderzoek toe te spitsen 
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op twee onderwerpen: (i) de thermodynamische eigenschappen van de degraderende 
hydrogelen (zoals de hierboven vermelde dextraan gelen) en (ii) de mechanische 
eigenschappen van de membraan (zoals de lipiden). 
     
Als thermodynamische parameter werd de zweldruk geëvalueerd van de hydrogel 
kern. De zweldruk bestaat uit een som van twee termen: de osmotische druk die expansie 
van het netwerk veroorzaakt en de elastische druk die deze expansie tegenwerkt. 
Aangezien een membraan omgeven degraderend hydrogel een druk zal opbouwen in 
functie van de tijd, is het vrij duidelijk dat deze eigenschappen bepalend zijn voor het 
barsten van de membraan. Om voldoende inzicht te krijgen in de evolutie van de zweldruk 
die optreedt tijdens hydrogel degradatie, werd een diepgaande analyse van de 
thermodynamische eigenschappen van de degraderende hydrogelen uitgevoerd. 
Tot onze verbazing waren er geen referenties te vinden die de karakterisatie van de 
zweldruk van degraderende hydrogelen gedetailleerd beschreven.  Er werd dan ook 
besloten zelf een methode te ontwikkelen.  De methode is gebaseerd op osmotische 
ontzwelling en laat toe de zweldruk van een al dan niet degraderend hydrogel te bepalen. 
Dex-HEMA hydrogelen met verschillende samenstelling werden aangemaakt door de dex-
HEMA concentratie en de substitutiegraad van het dex-HEMA (DS, aantal hydroxyethyl 
methacrylaatgroepen per 100 glucopyranose eenheden) te variëren. Uit reologische 
metingen en bepalingen van de suiker vrijstellingsproducten bleek dat de degradatie 
kinetiek van de hydrogelen sterk afhankelijk is van de gebruikte samenstelling. Het effect 
van de degradatie op de zweldruk werd bestudeerd op de dex-HEMA hydrogel met de 
kortste degradatietijd (namelijk dex-HEMA DS2.9; 25%). Op ieder ogenblik van de 
degradatie kon de evolutie van de zweldruk beschreven worden door de volgende 
vergelijking Πsw = A(ϕn–ϕe,tn-1/3ϕ1/3), waarbij ϕe,t de concentratie is van de gezwollen gel op 
tijdstip t, en A en n constanten zijn. Een heel opmerkelijk zweldruk profiel werd bekomen [zie  
Figure 2B, Chapter 3]. Na een initiële fase waarin de zweldruk slechts weinig toenam, volgde op 
het eind van de degradatie een plotse en sterke stijging in zweldruk. De lag fase in de zweldruk 
gedurende de eerste 15 dagen van de dex-HEMA degradatie kan verklaard worden door de daling 
in elastische druk. De plotse toename in zweldruk op het einde van de degradatie kan verklaard 
worden door het feit dat alleen op het einde van de degradatie (dicht bij de ‘gel-sol transitie’) de 
vrije dextraan ketens bijdragen tot de osmotische druk. Vóór de ‘gel-sol transitie’ gedroegen de 
dextraan ketens zich als additionele polymeer netwerk ketens en bleven ze als het ware fysisch 
gevangen in de gel (het netwerk). 
We vroegen ons af of we dit opmerkelijk zweldruk profiel konden bevestigen door de 
degraderende dex-HEMA gels na te bootsen met behulp van niet gedegradeerd dex-HEMA gels 
die verschillende hoeveelheden vrij dextraan (afbraakproduct) bevatten. En inderdaad, dex-HEMA 
hydrogelen die een gekende hoeveelheid vrij dextraan bevatten vertoonden gelijke osmotische 
eigenschappen als gedeeltelijk gedegradeerde dex-HEMA gels [zie Figure 4, Chapter 3]. Om de 
degradatie gecontroleerde exploderende microsferen te gebruiken voor meervoudige gepulseerde 
geneesmiddelen vrijgave is het interessant de zweldrukken van hydrogelen met verschillende 
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degradatie kinetiek te kennen. Zweldruk versus degradatie tijd grafieken werden bekomen door de 
zweldruk profielen van de dex-HEMA/dextraan hydrogelen te combineren met dextraan release 
curven van de degraderende dex-HEMA gelen. Zoals verwacht, waren de bekomen zweldruk 
profielen sterk afhankelijk van zowel de gebruikte dex-HEMA concentratie als van de gebruikte 
substitutiegraad [zie Figure 6, Chapter 3]. De initiële waarde van de elastische druk, de hoogte 
van het plateau van de osmotische druk en de maximale zweldruk (op het einde van de degradatie) 
stegen met toenemende dex-HEMA concentratie. Toename van de substitutiegraad resulteerde in 
een hoger aantal knooppunten wat gereflecteerd werd in een hogere initiële elasticiteits modulus. 
Een toename in knooppunten (door toename van DS en/of concentratie) resulteerde bovendien ook 
in een toename van de degradatie tijd en bijgevolg ook in de toename van tijdsduur vooraleer een 
welbepaalde zweldruk werd bereikt. 
Omdat de osmotische ontzwellingsmethode ter bepaling van de zweldruk van 
degraderende hydrogelen enorm tijdsrovend is en veel materiaal verbruikt, werd er een 
osmometer ontwikkeld voor de bepaling van de thermodynamische eigenschappen van de 
bestudeerde dex-HEMA gels [zie Figure 2, Chapter 4]. De veranderingen in zweldrukken 
van de farmaceutische hydrogelen die optreden tengevolge van degradatie worden 
gemeten door een hydrogel te fixeren tussen een rigide semi-permeabele membraan en het 
diafragma van een druk transducer. De reactie tijd van de sensor bedroeg 3 uren voor 
polymeer oplossingen en 6 uren voor gels. Het toestel werd gevalideerd met behulp van 
polymeer oplossingen (dextraan en poly(ethylene)glycol (PEG)) met gekende osmotische 
druk. Zowel voor de PEG-oplossingen als voor de dextraan oplossingen kwamen de 
gemeten data overeen met literatuur gegevens. In een volgende stap werd de zweldruk 
gemeten van een dex-MA (DS3.1; 25%) gel in de osmometer en anderzijds ook door 
middel van osmotische ontzwelling. Ongeveer 64 ± 10 kPa mechanische druk en 69 kPa 
osmotische druk was noodzakelijk om het volume van de hydrogel constant te houden. 
Bijgevolg konden we concluderen dat beide methoden om zweldrukken te meten 
vergelijkbaar resultaat opleveren. In een laatste stap werd het toestel geëvalueerd voor de 
meting van de zweldruk van degraderende hydrogelen. Hiervoor werd zowel een 
enzymatisch degraderend hydrogel nl. dex-MA/dextranase alsook een chemisch 
hydrolyserend hydrogel uitgekozen. De veranderingen in osmotische eigenschappen van 
de dex-MA/dextranase gelen konden gemakkelijk gevolgd worden. Maar spijtig genoeg 
was dat niet het geval voor de dex-HEMA hydrogelen. We kunnen dus stellen dat voor het 
meten van de zweldruk van degraderende hydrogelen, zowel de samenstelling (cfr. gels 
die krimpen kunnen niet gemeten worden in de osmometer) als het mechanisme van 
degradatie van de gel bepalend is of de osmometer een geschikt alternatief vormt voor de 
osmotische ontzwellingsmethode.    
 
Nadat een goed inzicht verkregen werd in de methoden om zweldrukken te 
evalueren van degraderende hydrogels werd een studie opgezet omtrent hun degradatie. 
De invloed van het degradatiemechanisme werd geëvalueerd. Er zijn twee 
degradatiemechanismen mogelijk voor de bulk degradatie van een hydrogel: degradatie 
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van het polymeer (de ruggengraat van het netwerk) en degradatie van de knooppunten.  
Dex-MA hydrogelen kunnen worden afgebroken door dextranase in te sluiten tijdens de 
gelering van de dex-MA oplossingen.  Dextranase knipt in de dex-MA ketens.  Om 
afbraak door degradatie van de knooppunten te evalueren werden dextraan hydroxyethyl 
methacrylaat (dex-HEMA) hydrogelen onderzocht.  Deze hebben een hydrolyseerbare 
groep ter hoogte van de knooppunten.  Zowel de elasticiteit, de vrijstelling van de 
degradatie producten, de zwelling en de zweldruk van de hierboven vermelde hydrogelen 
werden gemeten. De studie toonde dat het degradatiemechanisme vooral een grote invloed 
heeft op de vrijstelling van de degradatie producten (oligosacchariden voor dex-MA 
/dextranase gels en dextraan in het geval van dex-HEMA gels) en op het zweldruk 
verloop. In het geval van de dex-MA/dextranase gels (degradatie ter hoogte van de 
ruggegraat) steeg de zweldruk eerder continu [zie Figure 4, Chapter 5]. In het geval van de 
dex-HEMA gels (degradatie t.h.v de knooppunten) hebben we een discontinu verloop van 
de zweldruk dat gekenmerkt werd door een plotse stijging in zweldruk op het einde van de 
degradatie. We toonden aan dat de stijging in zweldruk van de dex-MA/dextranase gels 
bijna volledig te wijten is aan de toename in osmotische druk gedurende de dex-MA 
degradatie. Voor de degraderende dex-HEMA gels kon het zweldruk profiel initieel 
verklaard worden door een daling in elastische druk, aangezien gedurende een substantiële 
periode van de degradatie de osmotische druk niet veranderde. Bij volledige degradatie is 
de zweldruk gelijk aan de osmotische druk van de oplossing met degradatie producten. 
Gezien het grote verschil in molecuul gewicht van de afbraakproducten van beide gelen, 
was het vanzelfsprekend dat de finale druk veel hoger was voor de dex-MA gels dan voor 
de dex-HEMA gels. 
Het opmerkelijk zweldruk profiel van de degraderende dex-HEMA gels is ideaal om 
een membraan te laten barsten. De plotse toename in zweldruk op het einde van de 
degradatie zal de tijdsduur van geneesmiddelen vrijgave beperken die zou kunnen 
veroorzaakt worden door niet homogene eigenschappen van de membraan en variatie in de 
microgel grootte. In de rest van dit werk werd dus geopteerd om dex-HEMA microgelen 
als kernmateriaal van onze exploderende microsferen te gebruiken. 
Aangezien het slagen van ons concept niet alleen bepaald wordt door de 
thermodynamische eigenschappen van de kern maar ook door de mechanische 
eigenschappen van de membraan, werd in een volgende stap de membraan bestudeerd. We 
stelden ons de vraag welke membraan zou resulteren in een uniek membraan omgeven 
hydrogel systeem, dat zijn geneesmiddelen plots vrijgeeft door het barsten van de 
membraan ten gevolge van de osmotische druk, opgebouwd tijdens hydrogel degradatie. 
Lipiden bezitten ideale eigenschappen zoals een voldoende water permeabiliteit en een 
beperkte permeabiliteit voor geneesmiddelen en osmotische agentia. De treksterkte van de 
membranen werd geëvalueerd door de carboxyfluoresceïne vrijgave uit lipid vesikels met 
verschillende samenstellingen te bepalen. De carboxyfluoresceïne vrijgave trad op ten 
gevolge van een osmotische gradient tussen de vesikel inhoud en de omgevingsvloeistof 
die resulteerde in vesikel lysis. Gebruik makend van de wet van Laplace, konden we 
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berekenen dat voor 3 µm lipo-gels (lipid gecoate microgelen) de inwendige druk nodig 
voor een breuk in de membraan, tussen de 85 en 120 kPa lag, afhankelijk van de lipide 
samenstelling. Aangezien door degradatie van dex-HEMA hydrogelen een zweldruk van 
75-150 kPa kon bereikt worden, konden we besluiten dat, theoretisch gezien, de 
degraderende dex-HEMA gels in staat zouden zijn de bestudeerde lipid membranen te 
doen scheuren. Het leggen van een lipid membraan op microgelen was echter niet evident. 
Enkel door introductie van DMAEMA en MAA, waardoor respectievelijk positief en 
negatief geladen dex-HEMA microgelen verkregen werden, konden we lipid gecoate 
microgelen bekomen. De lipid coating is gebaseerd op elektrostatische interactie tussen de 
geladen microgels en de tegenovergesteld geladen lipid membraan (SOPC:DOPA en 
SOPC:DOTAP). De coating van de microgels werd gevisualiseerd met behulp van 
confocale laser scanning microscopie en bevestigd door middel van zeta-potentiaal 
metingen en elektronen microscopie. 100% coatingsefficiëntie en een mooie core-shell 
structuur werden bekomen [zie Figure 4, Chapter 6]. In een laatste stap, als kers op de taart, 
werd de ‘proof of principle’ geëvalueerd. Exploderende microsferen, namelijk de lipide 
gecoate microgelen bestaan [zie Figure 8, Chapter 6]! Met behulp van CLSM werd de 
degradatie van zowel gecoate als niet-gecoate microgelen gevolgd. Om de hydrolyse van 
het dex-HEMA de versnellen werden ze ondergedompeld in een 0.5 M NaOH oplossing. 
Zowel de gecoate als niet gecoate microgelen begonnen te zwellen, de zwelling nam toe 
naar het einde van de degradatie. De niet gecoate microgels vloeiden open in de 
omgevingsvloeistof. De gecoate microgelen daarentegen vertoonden plotseling een 
explosie (een barsten) van de lipide membraan met vrijstelling van de inhoud! De explosie 
zou kunnen veroorzaakt worden door de aanwezigheid van het NaOH. Daarom werden 
gecoate en niet gecoate dex-MA hydrogelen gevolgd onder de CLSM in identieke 
omstandigheden. De dex-MA hydrogelen degradeerden niet in aanwezigheid van NaOH. 
Bovendien werd er na geruime tijd geen visuele schade van de lipide membraan 
vastgesteld. We kunnen dus besluiten dat exploderende lipide gecoate microgelen bestaan 
en dat die explosie veroorzaakt werd door de inwendige osmotische druk die ontstond ten 
gevolge van de microgel degradatie.                
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